Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 10150. Отображено 100.
10-05-2012 дата публикации

Efficient and scalable process for the manufacture of fondaparinux sodium

Номер: US20120116066A1
Автор: Chun Ma, Kevin K. Ohrr, Payal P. Patel, Sourena Nadji
Принадлежит: Reliable Biopharmaceutical LLC

The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.

Подробнее
Номер записи: 1
02-08-2012 дата публикации

Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules

Номер: US20120196285A1
Автор: Jan Godoski, Patricia Okamoto, Thomas Scholl
Принадлежит: Esoterix Genetic Laboratories LLC

Methods for enriching specific microparticles, such as fetal microparticles or disease specific microparticles, in a biological sample are disclosed. In certain embodiments, the methods include combining a biological sample with a molecule that binds specific microparticles, and separating fractions of the biological sample, wherein the fraction that contains the binding molecule is enriched for the specific microparticles. Also disclosed are methods for enriching fetal nucleic acids by enriching fetal microparticles in a fraction of the biological sample and isolating nucleic acids from the enriched fraction. Methods for facilitating prenatal diagnosis of fetal chromosomal abnormalities are disclosed. In certain embodiments, the methods include combining a biological sample with a molecule that binds fetal microparticles, separating fractions of the biological sample, isolating nucleic acids from the fraction enriched for fetal microparticles, and analyzing the nucleic acids for the presence of a mutation.

Подробнее
Номер записи: 2
02-08-2012 дата публикации

Isolation of nucleic acids

Номер: US20120197009A1
Автор: Matthew John Baker
Принадлежит: Life Technologies Corp

A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.

Подробнее
Номер записи: 3
09-08-2012 дата публикации

Enhanced natural sweetener and method of making

Номер: US20120201952A1
Автор: Juan L. Navia, Steven J. Catani
Принадлежит: Mcneil Nutritionals Llc

A natural sweetening composition comprising a crude mixture of at least one plant based natural high intensity sweetening compound, the sweetening composition made by the process comprising (a) the step of steam stripping the crude mixture; and (b) at least one step of filtering the crude mixture.

Подробнее
Номер записи: 4
30-08-2012 дата публикации

Method for the manufacture of 2-fluoro-ara-adenine

Номер: US20120220762A1
Автор: Clemens Bothe, Joachim Rehse, Mathias Berwe
Принадлежит: Alcafleu Management GmbH and Co KG

A method is described for the manufacture of pure 2-fluoro-ara-adenine of Formula (I) from 2-fluoro-ara-adenine triacetate using potassium carbonate (K 2 CO 3 ), wherein the 2-fluoro-ara-adenine has a reduced dimer contents, as well as the compound 2-fluoro-ara-adenine having a dimer contents of ≦0.3%.

Подробнее
Номер записи: 5
22-11-2012 дата публикации

Method for isolating small rna

Номер: US20120295328A1
Автор: Ralf Wyrich, Thorsten Voss
Принадлежит: QIAGEN GmbH

A method for isolating small RNA from a sample is provided, the method comprising binding the RNA to silica particles by contacting the sample with a) at least one alcohol, b) at least one chaotropic salt comprising a chaotropic anion selected from the group consisting of trichloroacetate, perchlorate and trifluoroacetate and c) silica particles and separating the bound RNA from the rest of the sample. The present invention also provides compositions and kits to efficiently isolate small RNA molecules from samples, in particular biological samples such as blood, blood products tissue and body fluids.

Подробнее
Номер записи: 6
06-12-2012 дата публикации

Microprocessing for preparing a polycondensate

Номер: US20120309956A1
Автор: Bruno Frederic Stengel, Christof Franz Kuesters, J. Brandner, W. Benzinger
Принадлежит: Cargill Inc

The present invention relates to a process for preparing polydextrose by using a microdevice. It further relates to the use of a microdevice for the polycondesation reactions.

Подробнее
Номер записи: 7
14-03-2013 дата публикации

NOVEL PROCESS

Номер: US20130066064A1
Автор: CHARLES Philippe, GELDHOF Geoffroy, Mancuso Vincent
Принадлежит:

A single-phase LPS extraction composition comprising water, an alcohol and a further organic solvent, where the amount of water is between about 0.8 to 1.2% (v/v). 1. An LPS extraction composition comprising water , an alcohol and a further organic solvent.2. The composition of wherein the LPS extraction composition is single-phase.3. The composition of or wherein the amount of water in the LPS extraction composition is between about 0.1 and about 1.5% (v/v).4. The composition of any of to wherein the amount of water is about 1% (v/v).5. The composition of any of to wherein the amount of water is about 0.5% (v/v).6. The composition of any of to wherein the alcohol is selected from the list: methanol claim 1 , ethanol claim 1 , isopropanol or butanol.7. The composition of any of to wherein the percentage of alcohol in the LPS extraction composition is between about 5% and about 40% (v/v).8. The composition of wherein the percentage of alcohol is between about 10% (v/v) and about 30% (v/v).9. The composition of any preceding claim wherein the further organic solvent is selected from the group: chloroform claim 7 , alkanes claim 7 , toluene and petroleum ether.10. The composition of wherein the alkane is selected from the group: isooctane claim 9 , ethane claim 9 , heptane and hexane.11. The composition of any preceding claim wherein the percentage of the further organic solvent in the LPS extraction composition is between about 60% (v/v) and about 95% (v/v).12. The composition of wherein the percentage of the further organic solvent is between about 75% (v/v) and about 90% (v/v).13. The composition of any of to wherein the LPS extraction solution comprises chloroform claim 11 , methanol and water.14. The composition of any of to wherein the LPS extraction composition comprises an alkane claim 11 , ethanol and water.15. A composition according to any of to for use in the extraction of LPS from gram negative bacterial cells.16. Use of an LPS extraction composition ...

Подробнее
Номер записи: 8
21-03-2013 дата публикации

HIGH-PURITY STEVIOL GLYCOSIDES

Номер: US20130071339A1
Автор: MARKOSYAN Avetik
Принадлежит:

Methods of preparing highly purified steviol glycosides, particularly Rebaudioside D, are described. The methods include purification from the extraction stage of the Bertoni plant, purification of steviol glycoside mixtures, Rebaudioside D and Rebaudioside A from a commercial Stevia extract, and purification of Rebaudioside D from remaining solutions obtained after isolation and purification of Rebaudioside A and a high purity mixture of steviol glycosides. The methods are useful for producing high purity Rebaudioside D, Rebaudioside A, and steviol glycoside mixtures. The high purity steviol glycosides are useful as non-caloric sweeteners in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums. 1. A method for purifying steviol glycosides , comprising the steps of:a. providing a solution of steviol glycosides;b. passing the solution of steviol glycosides through a multi-column system including a plurality of columns packed with an adsorbent resin, to obtain at least one column having adsorbed steviol glycosides;c. removing impurities from the multi-column system; andd. eluting the adsorbed steviol glycosides from the at least one column, to obtain an eluted solution comprising steviol glycosides.2. The method of claim 1 , wherein impurities are removed by eluting the multi-column system with a washing solution.3. The method of claim 2 , wherein the washing solution comprises an aqueous alcohol solution having a water to alcohol ratio ranging from about 99.9:0.1 to about 60:40.4. The method of claim 1 , wherein the adsorbed steviol glycosides are eluted with an aqueous alcohol solution having a water to alcohol ratio ranging from about 60:40 to about 0.1:99.9.5. The method of claim 1 , wherein at least two columns of the plurality of columns are connected in series.6. The method of claim 1 , wherein at least two columns of the plurality of columns are connected in parallel.7. The method of claim 1 , ...

Подробнее
Номер записи: 9
21-03-2013 дата публикации

REBAUDIOSIDE B AND DERIVATIVES

Номер: US20130071537A1
Автор: Deng Mingming, Ding Jien, Shi Jingang, Wang Hansheng, Wu Yanyan
Принадлежит: E.P.C (Beijing) Plant Pharmaceutical Technology Co., Ltd

The invention describes compositions that include a sweetener and a salt of a steviol glycoside, wherein the concentration of the components provide an improved taste profile where bitterness, after taste and/or lingering of the sweetener is decreased or eliminated. 2. The purified compound according to claim 1 , wherein M is a sodium or potassium ion.3. The purified compound according to either claim 1 , wherein the sugar is a monosaccharide or an oligosaccharide.4. The purified compound according to claim 3 , wherein the monosaccharide is glucose (dextrose) claim 3 , fructose (levulose) claim 3 , galactose claim 3 , rhamnose claim 3 , xylose and/or ribose.5. The purified compound according to claim 3 , wherein the oligosaccharide is sucrose claim 3 , maltose claim 3 , lactose claim 3 , -glucose-glucose claim 3 , -glucose(-glucose)-glucose claim 3 , -glucose(-rhamnose)-glucose.6. The purified compound according to claim 5 , wherein M is a potassium ion and R is glucose(-glucose-)glucose.7. The purified compound according to claim 5 , wherein M is a sodium ion and R is glucose(-glucose)-glucose.8. A process to prepare a carboxylic acid salt of steviol or a steviol glycoside claim 5 , comprising the step of:reacting steviol or a steviol glycoside with a base, such that a carboxylic acid salt is formed.9. The process of any of claim 8 , wherein the steviol glycoside is raudioside A claim 8 , B claim 8 , D or mixtures thereof.10stevia. A process to prepare a carboxylic acid salt of a extract claim 8 , comprising the step of:{'i': stevia', 'stevia, 'reacting the extract with a base, such that a carboxylic acid salt is formed with one or more constituents of the extract.'}11stevia. The process of claim 10 , wherein the extract constituents comprise one or more of raudioside A claim 10 , B claim 10 , D or mixtures thereof.12. A purified rebaudioside B (RB) sweetener consisting essentially of RB.13. The purified rebaudioside B (RB) sweetener of claim 12 , wherein the ...

Подробнее
Номер записи: 10
21-03-2013 дата публикации

RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END

Номер: US20130072670A1
Автор: Bajpal Satya P., Pandey Divya, Srivastava Naveen P., Srivastava Suresh C.
Принадлежит: ChemGenes Corporation

The present invention relates to novel phosphoramidites, A-n-bz, C-n-bz, C-n-ac, G-n-ac and U are produced with an HPLC purity of greater than 98% and P NMR purity greater than 99%. A novel process of reverse 5′→3′ directed synthesis of RNA oligomers has been developed and disclosed. Using that method demonstrated high quality RNA synthesis with coupling efficiency approaching 99%. 2. The process according claim 1 , wherein L is cholesterol with the linker or the spacer claim 1 , and n=19.3. The process according to claim 1 , wherein L is polyethyleneglycol (PEG) claim 1 , and n=19.4. An RNA oligonucleotide claim 1 , wherein the RNA oligonucleotide is synthesized by the process according to . This application is a continuation application to U.S. application Ser. No. 12/584,625, filed Sep. 8, 2009, which in turn claims priority to U.S. Provisional Application Ser. No. 61/191,065, filed on Sep. 6, 2008. The entire teachings of the above applications are incorporated herein by reference.This invention relates to the synthesis of novel RNA monomer phosphoramidites, and corresponding solid supports that are suitable for a novel method of RNA oligonucleotide synthesis in reverse 5′→3′ direction. This approach leads to very clean oligonucleotide synthesis allowing for introduction of various modifications at the 3′-end cleanly and efficiently in order to produce high purity and therapeutic grade RNA oligonucleotides.Defined sequence RNA synthesis in the 3′→5′ direction is now well established and currently in use for synthesis and development of a vast variety of therapeutic grade RNA aptamers, tRNAs, siRNA and biologically active RNA molecules. This approach utilizes a ribonucleoside with suitable N-protecting group: generally 5′-Protecting group, the most popular being dimethoxytriphenyl, i.e. the DMT group; 2′-protecting group, out of which most popular is t-Butyldimethylsilyl ether; and, a 3′-phosphoramidite, the most popular of which is cyanoethyl diisopropyl ( ...

Подробнее
Номер записи: 11
21-03-2013 дата публикации

Novel Process for the Recovery of Beta Acetylfuranoside

Номер: US20130072674A1
Автор: BEHRINGER Martin, Junghans Bernd, Knipp Bernhard, Pfeil Bernhard, Zieres Gerald
Принадлежит: Hoffmann-La Roche Inc.

There is provided an improved method for the recovery of residual, unseparated β-ACF from reaction mixtures remaining from an initial synthesis of ACF, which is in particular usable on a large industrial scale, more particularly in the production of capecitabine. 1. A method for recovery of initially not separated β-ACF from mother liquor remaining from the synthesis of ACF , wherein the β-ACF is recovered by a combination of at least one distillation method and at least one chemical reaction step.2. The method according to comprising the following sequential steps:a) Evaporation to less than 1% residual solvent of the mother liquor remaining from an initial synthesis of ACF, to increase the content of residual α/β-ACF from about 8 to 15 weight-% to about 25 to 45 weight-%, followed by distillation to about 60 to 80 weight-% and subsequent crystallization of β-ACF out of the distillate by adding a suitable solvent;b) Chemical conversion of α/β-ACF mixture remaining in the mother liquor of step a), to β-ACF by de-acetylation and subsequent re-acetylation, followed by crystallization of β-ACF by addition of a suitable solvent;c) Optional repetition of step a) and b) in a sequential (clockwise) cyclic process.3. The process according to claim 2 , wherein the distillation to about 60 to 80 weight-% of step a) is carried out at 1 to 3 mbar and 200 to 210° C. heating temperature in a continuous thin-film evaporator.4. The process according to claim 3 , wherein step b) comprises the de-acetylation of α/β-ACF in the presence of a suitable base claim 3 , followed by neutralization with a suitable acid and further followed by the re-acetylation reaction in the presence of suitable base claim 3 , a suitable catalyst and a suitable acetylating agent. This application is a continuation of U.S. application Ser. No. 12/690,167, filed Jan. 20, 2010, now Pending, which claims the benefit of European Patent Application No. 09151384.6, filed Jan. 27, 2009, which is hereby incorporated ...

Подробнее
Номер записи: 12
04-04-2013 дата публикации

PROCESS FOR THE SEPARATION OF LIGNINS AND SUGARS FROM AN EXTRACTION LIQUOR

Номер: US20130085269A1
Автор: BENJELLOUN MLAYAH Bouchra, DELMAS Michel
Принадлежит:

A process for the separation of lignins and sugars from an extracted liquor, including, in the form of dry matter (DM), lignins and sugars, includes: a) concentrating the extracted liquor, in order to obtain a liquor having dry matter in a proportion of between 60 and 70%; b) mixing the concentrated liquor with water in equal parts by weight; c) stirring the mixture in order to disperse the lignins and to obtain a stable suspending of the lignins; d) filtering the solution, wherein the mixing is carried out by introducing the concentrated liquor into the water; and the temperature of the solution, during the suspending, is between 50° C. and 60° C. 2. Process according to claim 1 , characterized in that the said stirring of the solution is carried out by rotating.3. Process according to claim 1 , characterized in that claim 1 , after the filtration stage d) claim 1 , the filtered material is dried in order to obtain lignins as a powder claim 1 , the size of the particles of which is between 20 and 50 microns.4. Process according to claim 1 , characterized in that the said dry matter comprises claim 1 , by weight claim 1 , approximately 50% of lignins and approximately 50% of sugars and other products.5. Process according to claim 1 , characterized in that claim 1 , at 50° C. claim 1 , the viscosity of the solution is equal to approximately 0.26 Pa·s and the density of the solution is equal to approximately 1.074.6. Process according to claim 1 , characterized in that the suspension obtained in stage c) is stable claim 1 , at ambient temperature claim 1 , for at least two hours.7. Process according to claim 1 , characterized in that the said extracted liquor is obtained from a process for the production of paper pulp claim 1 , lignins claim 1 , sugars and acetic acid which comprises the successive stages consisting (i) in bringing together annual or perennial plants claim 1 , used in all or part claim 1 , which constitute the initial lignocellulose starting material ...

Подробнее
Номер записи: 13
04-04-2013 дата публикации

POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION

Номер: US20130085271A1
Автор: Fleischhacker Heinz, Jäschke Andres, Kliem Christian, Lorenz Peter, Schoch Juliane, Wiessler Manfred
Принадлежит:

The present invention concerns a method and a kit for the post-synthetic modification of nucleic acids via an inverse Diels-Alder reaction. 1. A method for the post-synthetic modification of nucleic acids , comprising the following steps:(a) preparing norbornene or trans-cyclooctene-modified oligonucleotides(b) preparing modified tetrazines, and(c) reacting the norbornene-modified oligonucleotides with the modified tetrazines via inverse Diels Alder reaction.2. The method of claim 1 , wherein the tetrazines are modified with a compound selected from the group consisting of fluorescent claim 1 , luminescent or phosphorescent dyes claim 1 , and affinity tags.3. The method of claim 1 , wherein the oligonucleotide is singly or multiply modified.4. The method of claim 3 , wherein the oligonucleotide is modified terminally and/or internally.5. The method of claim 4 , wherein the terminal modification is 3′and/or 5′.6. The method of claim 1 , wherein the oligonucleotide has a length between 3 and 500 nucleotides.7. The method of claim 1 , wherein the oligonucleotide is single-stranded or double-stranded DNA or RNA claim 1 , a nucleic acid analog or chimera thereof with DNA and/or RNA or an enyzmatically modified PCR product.9. The method of claim 1 , wherein the tetrazine is labelled with one or more of fluorescent claim 1 , luminescent or phosphorescent dyes claim 1 , or tagged with one or more affinity tags.11. The method of claim 1 , wherein the inverse Diels Alder reaction between the modified oligonucleotide and the modified tetrazin uses equimolar amounts of both components if the oligonucleotide is below 100 nucleotides.12. The method of claim 1 , wherein the inverse Diels Alder reaction between the modified oligonucleotide and the modified tetrazin uses the tetrazine in 2-20-fold excess if the oligonucleotide is larger than 100 nucleotides.13. The method of claim 11 , wherein the inverse Diels Alder reaction takes place between 0 and 100° C. in aqueous media.14. ...

Подробнее
Номер записи: 14
18-04-2013 дата публикации

POLYNUCLEOTIDE CAPTURE MATERIALS, AND METHODS OF USING SAME

Номер: US20130096292A1
Автор: Brahmasandra Sundaresh N., Craig Elizaeth
Принадлежит: HandyLab, Inc.

Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations. 1. A method for isolating polynucleotides from a cell-containing sample in a process tube , the method comprising:contacting the sample in the process tube with a lysis solution having a pH between 4 and 8, thereby releasing polynucleotides from the cells in the cell-containing sample;contacting the sample in the process tube with a plurality of magnetic binding particles coated in PAMAM, wherein the polynucleotides becomes reversibly bound to the PAMAM, thereby creating binding particles bound with polynucleotides and a solution containing residual cellular material in the process tube;compacting the binding particles bound with the polynucleotides in the process tube by positioning a magnet in communication with the binding particles;removing the solution containing residual cellular material from the process tube;washing the binding particles with a solution having a pH≦9, thereby retaining the polynucleotides bound to the binding particles; andcontacting the binding particles bound with polynucleotides with a solution having a pH≧9 to release the polynucleotides from the PAMAM on the binding particles, thereby isolating the polynucleotides from the cell-containing sample.2. The method of claim 1 , wherein the PAMAM on the binding particles comprises PAMAM (Generation 0).3. The method of claim 1 , wherein the polynucleotides comprise a mixture of DNA and RNA molecules.4. The method of claim 1 , wherein the contacting the compacted binding particles with a release solution further comprises contacting the binding particles with a ...

Подробнее
Номер записи: 15
25-04-2013 дата публикации

PROCESS FOR PERPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF

Номер: US20130102764A1
Автор: NADJI Sourena, Smoot James T., Vanartsdalen Joseph A.
Принадлежит: Reliable Biopharmaceutical Corporation

Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions. 114-. (canceled)18. The process of claim 17 , wherein deprotecting step (a) comprises treatment with a reagent selected from hydrazine claim 17 , hydrazine hydrate claim 17 , hydrazine acetate and RNH—NHwhere Ris aryl claim 17 , heteroaryl or alkyl.19. The process of claim 17 , wherein protecting step (b) comprises treatment with dihydropyran or a dihydropyran derivative and an acid selected from camphor sulfonic acid (CSA) claim 17 , hydrochloric acid (HCl) claim 17 , p-toluenesulfonic acid (pTsOH) and Lewis acids.25. The method of claim 24 , further comprising converting the fondaparinux-THP to fondaparinux sodium.27. The process of claim 26 , further comprising converting the resulting product to Fondaparinux sodium.33. The process of claim 32 , wherein the deprotecting step (a) comprises treatment with a reagent selected from hydrazine claim 32 , hydrazine hydrate claim 32 , hydrazine acetate and RNH—NHwhere Ris aryl claim 32 , heteroaryl or alkyl.34. The process of claim 33 , wherein the deprotecting step (a) comprises treatment with hydrazine.35. The process of claim 32 , wherein the protecting step (b) comprises treatment with dihydropyran or a dihydropyran derivative and an acid selected from camphor sulfonic acid (CSA) claim 32 , hydrochloric acid (HCl) claim 32 , p-toluenesulfonic acid (pTsOH) and Lewis acids.36. The process of claim 35 , wherein the protecting step (b) comprises treatment with dihydropyran and an acid selected from hydrochloric acid and p-toluenesulfonic acid.3743-. (canceled)44. A method of preparing an oligosaccharide comprising a β-glucosamine ...

Подробнее
Номер записи: 16
25-04-2013 дата публикации

Method of preparing sucralose-6-ester by catalysis and chlorination of phase transfer catalyst

Номер: US20130102773A1
Автор: Zhengyou WANG
Принадлежит: Hubei Yitai Pharmaceutical Co Ltd

A method of preparing sucralose-6-ester by catalysis and chlorination of phase transfer catalyst comprises the following steps: add phase transfer catalyst into a prepared Vilsmeier reagent and then drip in DMF solution of sucrose-6-ester at 5-10° C. to obtain a feed solution and after that maintain its temperature of the feed solution for 1-1.5 hours; next, increase temperature of the feed solution to 45-55° C. and maintain the temperature for 1-1.5 hours; next, increase the temperature to 75-85° C. and maintain the temperature for 1-1.5 hours; next, increase the temperature to 108-109° C., maintain the temperature for 2.5-3 hours and then remove a chlorine-containing solvent from the feed solution by concentration in reduced pressure for evaporation. After that, cool down the feed solution to room temperature and then pump in ammonia into the feed solution for neutralization.

Подробнее
Номер записи: 17
02-05-2013 дата публикации

Multidimensional Supramolecular Structures Essentially Made of Assembled I-Motif Tetramers

Номер: US20130109848A1
Автор: Laisne Aude, Leroy Jean-Louis, Pompon Denis
Принадлежит: Centre National De La Recherche Scientifique

The present invention pertains to a supramolecular structure based on i-motif tetramers of C—X—Coligonucleotides, wherein m and n are integers comprised between 2 and 9, and X is a linker such as A, T, G, a modified deoxynucleotide or a diol spacer. These supramolecular structures can be dissociated, when necessary, by a mere pH change. The present invention also relates to methods for obtaining such a supramolecular structure. 1. (canceled)2. A supramolecular structure comprising N C—X—C(SEQ ID No: 1) oligonucleotides , wherein m and n are integers comprised between 2 and 7 , preferably between 3 and 7 , X is selected in the group consisting of A , T , G , a modified deoxynucleotide and a diol spacer , N an integer ≧8 and wherein each oligonucleotide is part of an i-motif tetramer.3. The supramolecular structure of claim 2 , wherein m≠n.4. The supramolecular structure of claim 2 , wherein (m claim 2 , n) is selected in the group of (4 claim 2 , 7) and (7 claim 2 , 4).5. The supramolecular structure according to claim 2 , wherein X=G.6. The supramolecular structure according to claim 2 , which comprises oligonucleotides having different sequences.7. The supramolecular structure according to claim 6 , comprising oligonucleotides of sequence C—X—C(SEQ ID No: 1) and terminator oligonucleotides.8. The supramolecular structure according to claim 7 , wherein at least part of said terminator oligonucleotides are covalently linked to a reactive group.9. The supramolecular structure according to claim 2 , wherein N≧50.10. A process for producing a supramolecular structure according to claim 2 , wherein said process comprises the following steps:{'sub': m', 'n, '(i) incubating a solution of oligonucleotides of sequence C—X—C(SEQ ID No: 1) wherein n and m are integers comprised between 2 and 9, preferably between 3 and 7, and X is selected in the group consisting of A, T, G, a modified deoxynucleotide and a diol spacer, in a buffer having a pH in the range 3 to 6, and'}(ii) ...

Подробнее
Номер записи: 18
09-05-2013 дата публикации

CELL DISRUPTION

Номер: US20130115670A1
Автор: Edge David, Nazareth Nelson, Ward David
Принадлежит:

A process for the disruption of a biological cell comprising freezing, boiling or perhaps alternately freezing and boiling the material containing the biological cell using a thermoelectric cell a base face whereof is contiguous with a heat sink/source held at a substantially constant temperature and a working face . Apparatus for carrying out the disruption process comprises a peltier cell a base face of which is flexibly attached to a heat sink arranged to be kept at a constant temperature of around 50° C. and a working face of which is contiguous with a reaction vessel or a reaction vessel holder. Reversal of the voltage in the peltier cell enables the working face alternately to reach below freezing and above boiling temperatures, and/or with use of a resistive wire on the vessel holder for heating with the TEC used purely for cooling The peltier cell base face is constructed of materials which tend to inhibit disintegration of the peltier cell brought about by expansion and contraction under heat. 142-. (canceled)43. A process for the disruption of a biological cell to release contained material , comprising placing a target biological cell in a vessel , the vessel being in close proximity to a working surface of a thermoelectric cell the base face of which is in close proximity to a heat source/sink at a substantially constant temperature between the freezing and boiling temperatures of water , and applying an electric current to the thermoelectric cell to substantially change the temperature of the target biological cell.44. A process as claimed in and comprising reducing the temperature at the working face of the thermoelectric cell to freezing thus forming ice crystals in the target cells claim 43 , and then causing the ice to thaw.45. A process as claimed in and comprising heating the target cells to the boiling temperature thereof claim 43 , the sample then being allowed to cool.46. A process as claimed in and employing a thermal cycle comprising ...

Подробнее
Номер записи: 19
16-05-2013 дата публикации

METHOD FOR PURIFYING A TARGET NUCLEIC ACID

Номер: US20130122574A1
Автор: Voss Thorsten, Wyrich Ralf
Принадлежит: QIAGEN STRASSE 1

The present invention pertains to method for purifying at least a target nucleic acid from a sample, said method comprising at least the following steps: a) incubating the sample with at least one protein-degrading compound; b) binding the target nucleic acid to a solid phase; c) eluting the target nucleic acid from the solid phase; d) incubating the eluted target nucleic acid with at least one protein-degrading compound; e) binding the target nucleic acid again to a solid phase; f) optionally eluting the bound target nucleic acid from the solid phase. It was surprisingly found that performing a second protein digestion step after the target nucleic acid was bound and eluted from a solid phase before the nucleic acids are rebound to a solid phase is very efficient in reducing remaining protein contaminations in the isolated nucleic acid. 115.-. (canceled)16. A method for purifying at least one target nucleic acid from a sample , comprising:(A) incubating the sample with at least one protein-degrading compound,(B) binding the target nucleic acid to a solid phase,(C) eluting the target nucleic acid from the solid phase,(D) incubating the eluted target nucleic acid with at least one protein-degrading compound,(E) binding the target nucleic acid again to a solid phase, and(F) optionally eluting the bound target nucleic acid from the solid phase.17. The method of claim 16 , wherein the incubation in step (A) and/or step (D) is performed under conditions comprising one or more of the following(a) heating,(b) agitation,(c) the presence of salts,(d) the presence of chaotropic agents,(e) a pH value of between 6 to 9, and/or(f) an incubation period of at least 3 minutes.18. The method of claim 16 , wherein the at least one protein-degrading compound is a proteolytic enzyme.19. The method of claim 16 , wherein binding in step B) and/or step E) is performed under conditions having one or more of the following characteristics:(a) binding is performed in the presence of at least ...

Подробнее
Номер записи: 20
23-05-2013 дата публикации

METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE

Номер: US20130131334A1
Автор: Ágoston Károly, Bajza István, BØJSTRUP Marie, Boutet Julien, Dekany Gyula, Fanefjord Mette, Hederos Markus, Horvath Ference, Kovács-Pénzes Piroska, Kröger Lars, Olsson Johan, Pérez Figueroa Ignacio, Röhrig Christoph, Schroven Andreas, Vrasidas Ioannis
Принадлежит: Glycom A/S Danmarks Tekniske Universitet

The present invention relates to an improved synthesis of a trisaccharide of the formula (1), novel intermediates used in the synthesis and the preparation of the intermediates. 119-. (canceled)21. The method according to claim 20 , characterized in that the catalytic hydrogenolysis is carried out in water claim 20 , in one or more C-Calcohols claim 20 , in a mixture water and one or more C-Calcohols claim 20 , or in a mixture of water claim 20 , one or more C-Calcohols and acetic acid claim 20 , in the presence of palladium on charcoal or palladium black.22. The method according to claim 20 , characterized in that O-(2 claim 20 ,3 claim 20 ,4-tri-O-benzyl-α-L-fucopyranosyl)-(1→2)-O-β-D-galactopyranosyl-(1→4)-D-glucose of the general formula 1 in hydrated form claim 20 , in crystalline water free form or in a mixture of hydrated and crystalline water free forms is applied.24. The compound according to claim 23 , wherein Rand R claim 23 , independently from each other claim 23 , means benzyl claim 23 , 4-methylbenzyl claim 23 , benzyloxycarbonyl claim 23 , naphthylmethyl claim 23 , 3-phenylbenzyl claim 23 , 4-chlorobenzyl claim 23 , 4-methoxybenzyl claim 23 , 3 claim 23 ,4-dimethoxybenzyl claim 23 , 2 claim 23 ,4 claim 23 ,6-trimethylbenzyl or 2 claim 23 ,3 claim 23 ,4 claim 23 ,5 claim 23 ,6-pentamethylbenzyl claim 23 , benzyl or 4-methylbenzyl and Ris H.27. The method according to claim 26 , characterized in that the acid catalyzed mild hydrolysis is conducted in aqueous acetic acid solution.28. The method according to claim 26 , characterized in that compounds of general formula 2 claim 26 , wherein R and R′ mean methyl claim 26 , one of the Rand Rgroups or both Rand Rgroups are 4-methylbenzyl and Ris H claim 26 , is applied.31. The method according to claim 30 , characterized in that the acid catalyzed mild hydrolysis is carried out in ethyl acetate/acetonitrile/water wherein the proportion of the ethyl acetate is more than 40 v/v %.32. The method according to ...

Подробнее
Номер записи: 21
06-06-2013 дата публикации

METAL PARTICLES FOR SURFACE-ENHANCED RAMAN SCATTERING AND MOLECULAR SENSING

Номер: US20130141719A1
Автор: Furusho Hitoshi
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

There is provided a high-sensitive Raman scattering sensing by regulating in metal nanoparticles for enhanced Raman scattering, particularly the strength of the enhanced electric field by controlling the distance between the particles to impart very strong Raman scattering properties. A metal nanoparticle material for molecular sensing, the metal nanoparticle material comprising: a metal nanoparticle aggregate including three to ten metal nanoparticles connected to each other through an organic molecule so that adjacent metal nanoparticles are bonded and spaced apart a predetermined distance, the aggregate containing a Raman active molecule within a field applied to the aggregate, wherein the metal nanoparticle material emits enhanced Raman scattering light from the Raman active molecule in an enhanced electric field; a method for producing the metal nanoparticle material for molecular sensing; and a molecular sensing by use of the metal nanoparticle material for molecular sensing. 1. A metal nanoparticle material for molecular sensing , the metal nanoparticle material comprising:a metal nanoparticle aggregate including three to ten metal nanoparticles connected to each other through an organic molecule so that adjacent metal nanoparticles are bonded and spaced apart a predetermined distance, the aggregate containing a Raman active molecule within a field applied to the aggregate, whereinthe metal nanoparticle material emits enhanced Raman scattering light from the Raman active molecule in an enhanced electric field.2. The metal nanoparticle material for molecular sensing according to claim 1 , wherein the metal nanoparticles are of a metallic element having a resonance wavelength producing surface plasmon resonance in regions ranging from an ultraviolet region to an infrared region.3. The metal nanoparticle material for molecular sensing according to claim 1 , wherein the metal nanoparticles are particles having an average particle diameter of 1 nm to 100 nm.4. The ...

Подробнее
Номер записи: 22
06-06-2013 дата публикации

METHOD FOR PURIFYING REBAUDIOSIDE C

Номер: US20130144046A1
Автор: Chen Zhen
Принадлежит: International Flavors & Fragrances Inc.

The present invention is a method for purifying Rebaudioside C by subjecting “waste material,” generated during the Rebaudioside A manufacturing process, to liquid-liquid extraction and recrystallizing the Rebaudioside C. 1. A method for purifying Rebaudioside C comprising(a) extracting a material containing Rebaudioside C and depleted of Rebaudioside A with a solution of ethyl acetate and 1-butanol;(b) retaining the ethyl acetate and 1-butanol soluble fraction;(c) contacting the ethyl acetate and 1-butanol soluble fraction with a solution of acetone and water to recrystallize the Rebaudioside C; and(d) collecting the recrystallized Rebaudioside C thereby purifying Rebaudioside C.2. The method of claim 1 , wherein the ratio of ethyl acetate:1-butanol is 60-70:30-40.3. The method of claim 1 , wherein the ratio of acetone:water is 80-90:10-20.4. The method of claim 1 , wherein the material containing Rebaudioside C and depleted of Rebaudioside A comprises tetrahydrofuran and water.5. The method of claim 4 , wherein the ratio of tetrahydrofuran:water is 20-30:70-80.6. The method of claim 1 , further comprising the presteps of extracting the material containing Rebaudioside C and depleted of Rebaudioside A with a first solution of ethyl acetate:1-butanol (80-90:10-20) and discarding the ethyl acetate:1-butanol soluble fraction.7. The method of claim 1 , further comprising subjecting the recrystallized Rebaudioside C to a second recrystallization.8. The method of claim 7 , wherein the second recrystallization comprises a solution of 1-butanol:water (97:3).9. The method of claim 1 , further comprising washing the recrystallized Rebaudioside C with a solution of acetone:water (85:15). This application claims benefit from U.S. provisional application Ser. No. 61/561,483 filed Nov. 18, 2011, the contents of which are incorporated herein by reference in their entirety.The South American perennial Bertoni is known for its natural sweeteners. The sweetness of the plant is ...

Подробнее
Номер записи: 23
06-06-2013 дата публикации

SOLUTION FOR EXTRACTION OF RNA

Номер: US20130144049A1
Автор: Akiyama Hideo, Nobumasa Hitoshi, Yoshimoto Makiko
Принадлежит: Toray Industries, Inc.

A solution for extracting substantially pure RNA from a biological sample is disclosed. The solution for extracting RNA from a biological sample containing RNA and at least DNA comprises: 1. A solution for extracting RNA from a biological sample containing RNA and at least DNA , said solution comprising:(a) phenol in an amount of more than 50% by volume based on the total amount of said solution;(b) a polyol in an amount of 3 to 10% by volume based on the total amount of said solution;(c) a guanidinium salt at a concentration of 0.5 to 2.0 M based on the total amount of said solution;(d) a thiocyanate at a concentration of 0.1 to 0.5 M based on the total amount of said solution; and(e) a buffer for maintaining the pH of said solution at 4 to 6.2. The solution according to claim 1 , wherein the phenol concentration is 55 to 65% by volume based on the total amount of said solution.3. The solution according to claim 1 , further comprising an organic solvent for separating an aqueous layer.4. The solution according to claim 1 , wherein said biological sample is a culture liquid of cultured cells.5. The solution according to claim 1 , wherein said biological sample is a body fluid component of an organism.6. The solution according to claim 1 , wherein said biological sample is a blood component of an organism.7. A method for extracting RNA from a biological sample containing RNA and at least DNA claim 1 , said method comprising the steps of: (a) phenol in an amount of more than 50% by volume based on the total amount of said solution;', '(b) a polyol in an amount of 3 to 10% by volume based on the total amount of said solution;', '(c) a guanidinium salt at a concentration of 0.5 to 2.0 M based on the total amount of said solution;', '(d) a thiocyanate at a concentration of 0.1 to 0.5 M based on the total amount of said solution; and', '(e) a buffer for maintaining the pH of said solution at 4 to 6;, 'homogenizing said biological sample together with a solution ...

Подробнее
Номер записи: 24
06-06-2013 дата публикации

CRYSTAL FORM OF 4-ISOPROPYLPHENYL GLUCITOL COMPOUND AND PROCESS FOR PRODUCTION THEREOF

Номер: US20130144050A1
Автор: Imura Koreaki, KIMURA Yoshihiro, Matsushima Ayumi, Osaki Naoto
Принадлежит: TAISHO PHARMACEUTICAL CO., LTD.

A highly stable crystal of (1S)-1,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3,3-dimethyl-4-oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol, and a process for producing the crystal are provided. Specifically, an ethanolate having the following physical properties, and a plurality of other crystal forms transformed from the ethanolate are provided: 1. A crystal of an ethanolate of (1S)-1 ,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3 ,3-dimethyl-4-oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol having physical properties (a) to (c) mentioned below:(a) Having peaks at 2θ=5.9 degrees, 17.1 degrees, 17.6 degrees and 21.5 degrees in X-ray powder diffraction (Cu—Kα);{'sup': −1', '−1', '−1', '−1', '−1', '−1, '(b) Showing characteristic absorption bands at 3538 cm, 3357 cm, 2964 cm, 1673 cm, 1634 cmand 1505 cmin an infrared absorption spectrum; and'}(c) Having a melting point in a vicinity of 111° C.2. A process for producing a crystal having physical properties (a) to (c) mentioned below , comprising:dissolving (1S)-1,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3,3-dimethyl-4-oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol in ethanol or a mixture of ethanol and an organic solvent miscible with ethanol;then effecting crystallization at 0 to 80° C.; anddrying the resulting crystal at 50° C. or lower.(a) Having peaks at 2θ=5.9 degrees, 17.1 degrees, 17.6 degrees and 21.5 degrees in X-ray powder diffraction (Cu—Kα);{'sup': −1', '−1', '−1', '−1', '−1', '−1, '(b) Showing characteristic absorption bands at 3538 cm, 3357 cm, 2964 cm, 1673 cm, 1634 cmand 1505 cmin an infrared absorption spectrum; and'}(c) Having a melting point in a vicinity of 111° C.3. A crystal of (1S)-1 ,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]- ...

Подробнее
Номер записи: 25
20-06-2013 дата публикации

Alpha-selective glycosylation method

Номер: US20130158242A1
Автор: Chih-Yueh Liu, Chin-Sheng Chao, Kwok-Kong Tony Mong, Shao-Ru Lu
Принадлежит: National Chiao Tung University NCTU

The present invention provides an α-selective glycosylation method. The α-selective glycosylation method includes performing a reaction of a donor having a saccharide structure and a formamide-containing compound to form a glycosyl imidate compound; and in one pot environment, performing an addition reaction of the glycosyl imidate compound and an acceptor having a hydroxyl group to form an α-glycoside with high α-selectivity. The α-selective glycosylation method is applicable to the large scale production and easy to recover the formamide-containing compound.

Подробнее
Номер записи: 26
20-06-2013 дата публикации

PROCESS FOR CONJUGATION OF NHS ESTERS WITH OLIGONUCLEOTIDES

Номер: US20130158243A1
Автор: Ball Robert William
Принадлежит: SIGMA-ALDRICH CO. LLC

The present invention provides processes for the conjugation of NHS esters to amino-modified oligonucleotides. The processes provide the amino-modified oligonucleotide on a solid support such that conjugation can be carried out under conditions that can accommodate a wide variety of NHS esters and oligonucleotides. 1. A process for conjugating a N-hydroxysuccinimide ester with an amino-modified oligonucleotide , the process comprising contacting the N-hydroxysuccinimide ester with the amino-modified oligonucleotide , wherein the amino-modified oligonucleotide is non-covalently bound to an ion exchange support.3. The process of claim 1 , wherein Rcomprises a fluorescent moiety claim 1 , a dye claim 1 , or a label.4. The process of claim 1 , wherein the amino-modified oligonucleotide comprises from about 5 to about 500 bases.5. The process of claim 1 , wherein the amino-modified oligonucleotide has a mass-average molecular weight of about 500 to about 100 claim 1 ,000 Da.6. The process of claim 1 , wherein the amino-modified oligonucleotide has a mass-average molecular weight of about 1 claim 1 ,500 to about 40 claim 1 ,000 Da.7. The process of claim 1 , wherein the amino group comprising the amino-modified oligonucleotide is free during conjugation.8. The process of claim 1 , wherein conjugation is conducted in a non-aqueous environment.9. The process of claim 1 , wherein the ion exchange support comprises a strong base exchanger.10. The process of claim 1 , wherein the ion exchange support comprises a quaternary or tertiary amine.11. A process for conjugating an N-hydroxysuccinimide ester with an amino-modified oligonucleotide claim 1 , the process comprising contacting the N-hydroxysuccinimide ester with the amino-modified oligonucleotide bound to a solid support claim 1 , wherein the process is conducted in a non-aqueous environment.13. The process of claim 11 , wherein Rcomprises a fluorescent moiety claim 11 , a dye claim 11 , or a label.14. The process of claim ...

Подробнее
Номер записи: 27
27-06-2013 дата публикации

Process for the Purification of Rebaudioside A and Compositions Thereof

Номер: US20130164434A1
Автор: Bin Haja Mohideen Jamaluddin, Makarukpinyo Porntape, Pnita Chutasmit
Принадлежит: ALMENDRA PTE LTD.

There is provided processes for the purification of rebaudioside A from Steviol glycoside compositions, such as Stevia extracts. Also provided are pure compositions and formulations thereof of rebaudioside A with traces amounts of remaining steviol glycosides of less than 1%. Also provided are prepared foods, beverages, medicines and dietary supplements containing pure rebaudioside A. 1. A process of purifying rebaudioside A comprising:(a) forming a supersaturated solution of a steviol glycoside mixture comprising rebaudioside A and ethanol; and(b) exposing the solution to sonication.214-. (canceled)15. A process of purifying rebaudioside A comprising:(a) forming a supersaturated solution of a Steviol glycosides mixture comprising at least 65±1% of rebaudioside A, no more than 25±1% of stevioside and an impurity profile of no more 6.5±0.1% of rebaudioside C, 1.3±0.1% of rebaudioside F, and no more than 1.0±0.05% of remaining Steviol glycosides in a solvent mixture of absolute ethanol and water; and(b) exposing the solution to sonication.1617-. (canceled)18. Pure rebaudioside A having at least 98.7±0.1% of rebaudioside A and an impurity profile ofa. no more than 0.010±0.005% of rebaudioside B;b. no more than 0.010±0.005% of rebaudioside C;c. no more than 0.50±0.02% of rebaudioside F;d. no more than 0.55±0.005% of Stevioside;e. no more than 0.010±0.005% of Dulcoside A;f. no more than 0.010±0.005% of Rubusoside; andg. no more than 0.010±0.005% of Steviolbioside.1926-. (canceled)27. A method of purifying rebaudioside A comprising: forming a supersaturated solution of a Stevia extract in a solvent mixture of absolute ethanol and no more than about 2% water and isolating rebaudioside A.28. A method of purifying rebaudioside A comprising:(a) forming a supersaturated solution of a Stevia extract in a solvent mixture of absolute ethanol and water;(b) exposing the solution to sonication;(c) isolating a first composition comprising rebaudioside A;(d) forming a supersaturated ...

Подробнее
Номер записи: 28
27-06-2013 дата публикации

Method for isolating a target nucleic acid including small target nucleic acids with high yield

Номер: US20130164825A1
Автор: Gabriele Christoffel, Martin Schlumpberger, Vera HOLLÄNDER
Принадлежит: QIAGEN GmbH

The present invention pertains to a method for isolating a target nucleic acid including small target nucleic acids from a sample, said method comprising at least the following steps a) binding at least a portion of the target nucleic acid including small target nucleic acids to a nucleic acid binding solid phase comprised in a column by passing the sample through said column, b) performing an enzymatic and/or chemical treatment on the nucleic acid binding solid phase while the target nucleic acid is bound to said solid phase, c) collecting at least a portion of the small target nucleic acids released from the solid phase during said treatment of step b) as flow-through, d) contacting said flow-through which comprises small target nucleic acids mixed with a recovery solution with a nucleic acid binding solid phase for binding the contained small target nucleic acids to said nucleic acid binding solid phase, e) optionally performing an elution. The present invention results in a considerable increase in the yield of small target nucleic acids in the isolated target nucleic acid because it allows to efficiently capture and recover small target nucleic acids.

Подробнее
Номер записи: 29
27-06-2013 дата публикации

MICROFLUIDIC APPARATUS, METHOD, AND APPLICATIONS

Номер: US20130164826A1
Автор: Zhou Peng
Принадлежит: RHEONIX, INC.

A microfluidic apparatus, method, and associated applications utilize and apply to a formalin-fixed paraffin-embedded (FFPE) tissue sample and performing a liquid-liquid extraction to remove the paraffin from the tissue sample prior to a nucleic acid purification step. A microfluidic device includes a dedicated liquid-liquid extraction process vessel, a nucleic acid purification process component, and a nucleic acid amplification reactor. A liquid-liquid extraction and nucleic acid purification kit includes a microfluidic device capable of performing both a liquid-liquid extraction process and a nucleic acid purification process, including a dedicated liquid-liquid extraction process vessel, an immiscible liquid or a precursor phase thereof disposed in the vessel, a nucleic acid purification process component, a nucleic acid amplification reactor fluidically, and a supply of reagents suitable to enable the liquid-liquid extraction process and the nucleic acid purification process. 1. A method for nucleic acid purification , comprising:providing a formalin-fixed paraffin-embedded (FFPE) tissue sample in an aqueous solution having a density and a boiling point, in a vessel;providing an immiscible liquid or a precursor phase thereof, having a density that is less than the density of the aqueous solution and a boiling point that is greater than the boiling point of the aqueous solution, in the vessel; andperforming a liquid-liquid extraction to remove the paraffin from the tissue sample prior to a nucleic acid purification step.2. The method of claim 1 , further comprising performing the liquid-liquid extraction step and the nucleic acid purification step in a single microfluidic device.3. The method of claim 1 , further comprising providing a silicon oil as the immiscible liquid.4. The method of claim 1 , further comprising providing a mineral oil as the immiscible liquid.5. The method of claim 1 , further comprising providing a solid silicone oil/wax mixture as the ...

Подробнее
Номер записи: 30
27-06-2013 дата публикации

POLYMORPHS OF 2'-O-FUCOSYLLACTOSE AND PRODUCING THEREOF

Номер: US20130165406A1
Автор: Ágoston Ágnes, Ágoston Károly, Bajza István, Boutet Julien, Dekany Gyula, Demkó Sándor, Figueroa Pérez Ignacio, Hederos Markus, Horváth Ferenc, Kádár Gábor, Kalmár László, Kovács-Pénzes Piroska, Kröger Lars, Pipa Gergely, Risinger Christian, Röhrig Christoph, Schroven Andreas, Trinka Péter, Vrasidas Ioannis
Принадлежит: GLYCOM A/S

The present invention relates to novel polymorphs of the trisaccharide 2′-O-fucosyllactose (2-FL) of formula (1), methods for producing said polymorphs and their use in pharmaceutical or nutritional compositions. 1. Crystalline 2′-O-fucosyllactose polymorph II , characterized in that it displays X-ray powder diffraction reflections , based on a measurement using CuKα radiation , at 16.98±0.20 , 13.65±0.20 and 18.32±0.20 2Θ angles.2. The crystalline 2′-O-fucosyllactose polymorph II according to which is substantially pure.3. The crystalline 2′-O-fucosyllactose polymorph II according to which is substantially free from organic solvent and/or water.4. A method for producing crystalline 2′-O-fucosyllactose polymorph II according to claim 1 , characterized in that the crystallization is carried out from a solvent system comprising one or more C-Calcohols in the presence of seed crystals of crystalline 2′-O-fucosyllactose polymorph II according to .5. The method according to claim 4 , wherein the C-Calcohol is methanol and/or ethanol.6. The method according to claim 4 , wherein the solvent system further contains water.7. A method for producing crystalline 2′-O-fucosyllactose polymorph II according to claim 1 , characterized in that syrupy 2-FL claim 1 , solid 2-FL comprising amorphous 2-FL or any 2-FL polymorph(s) different to polymorph II claim 1 , or a mixture of amorphous 2-FL and any 2-FL polymorph(s) different to polymorph II is suspended in one or more less polar aprotic organic solvent.8. The method according to wherein the less polar aprotic organic solvent is an ester type solvent.9. 2′-O-Fucosyllactose polymorph I in polycrystalline or single crystal form claim 7 , characterized in that it displays X-ray powder diffraction reflections claim 7 , based on a measurement using CuKα radiation claim 7 , at 21.34±0.20 claim 7 , 20.92±0.20 and 18.37±0.20 2Θ angles.10. The crystalline 2′-O-fucosyllactose polymorph I according to in single crystal form claim 9 , ...

Подробнее
Номер записи: 31
04-07-2013 дата публикации

DERIVATIZATION OF OLIGOSACCHARIDES

Номер: US20130172548A1
Автор: Ágoston Ágnes, Ágoston Károly, Bajza István, Boutet Julien, Champion Elise, Dekany Gyula, Demkó Sándor, Figueroa Pérez Ignacio, Hedros Markus, Horváth Ferenc, Kalmár László, Kovacs Imre, Kovács-Pénzes Piroska, Kröger Lars, Pipa Gergely, Risinger Christian, Röhrig Christoph, Schroven Andreas, Trinka Péter, Vrasidas Ioannis
Принадлежит: Glycom A/S, Kgs.

A method for purifying, separating and/or isolating an oligosaccharide or a salt thereof is presented. An embodiment of the invention is based upon the formation of anomeric O-benzyl/substituted O-benzyl derivatives in a selective anomeric alkylation reaction. 2. The method according to claim 1 , wherein group R in compound R—X and compounds of general formula 2 is benzyl or 1- or 2-naphthylmethyl optionally substituted with one or more groups selected from phenyl claim 1 , alkyl or halogen.3. The method according to claim 1 , wherein the chromatography is reverse phase or size exclusion chromatography.5. The method according to claim 1 , wherein compounds of general formula 1a or 2a are selected from the group consisting of lacto-N-neotetraose claim 1 , para-lacto-N-hexaose claim 1 , para-lacto-N-neohexaose claim 1 , lacto-N-neohexaose claim 1 , para-lacto-N-octaose and lacto-N-neooctaose derivatives optionally substituted with one or more sialyl and/or fucosyl residue claim 1 , or salts of these compounds claim 1 , and compounds of general formula 1b or 2b are selected from the group consisting of lacto-N-tetraose claim 1 , lacto-N-hexaose claim 1 , lacto-N-octaose claim 1 , iso-lacto-N-octaose claim 1 , lacto-N-decaose and lacto-N-neodecaose derivatives optionally substituted with one or more sialyl and/or fucosyl residue claim 1 , or salts of these compounds.6. The method according to claim 4 , wherein compounds of general formula 1a claim 4 , 1b claim 4 , 1c claim 4 , 2a claim 4 , 2b or 2c are selected from the group consisting of 2′-O-fucosyllactose claim 4 , 3-O-fucosyllactose claim 4 , 2′ claim 4 ,3-di-O-fucosyllactose claim 4 , 3′-O-sialyllactose claim 4 , 6′-O-sialyllactose claim 4 , 3′-O-sialyl-3-O-fucosyllactose claim 4 , lacto-N-tetraose claim 4 , lacto-N-neotetraose claim 4 , Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc (LNFP-I) claim 4 , Galβ1-3(Fucα1-4) GlcNAcβ1-3Galβ1-4Glc (LNFP-II) claim 4 , Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc (LNFP-III) claim 4 , Galβ1- ...

Подробнее
Номер записи: 32
11-07-2013 дата публикации

OLIGONUCLEOTIDE SPECIFIC UPTAKE OF NANOCONJUGATES

Номер: US20130178610A1
Автор: Giljohann David A., Mirkin Chad A.
Принадлежит:

The present invention concerns nanoparticles functionalized with an oligonucleotide and a domain for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a nanoparticle that is taken up by a cell at an efficiency different than a nanoparticle functionalized with the same oligonucleotide but does not contain a domain. 1. A nanoparticle functionalized with an oligonucleotide and a domain , the nanoparticle having the property of being taken up by a cell at an efficiency different than a nanoparticle functionalized with the same oligonucleotide but lacking the domain.2. The nanoparticle of wherein the domain is located 5′ to the oligonucleotide.3. The nanoparticle of wherein the domain is located 3′ to the oligonucleotide.4. The nanoparticle of wherein the domain is located at an internal region within the oligonucleotide.5. The nanoparticle of wherein the domain is colinear with the oligonucleotide.6. The nanoparticle of functionalized with a second oligonucleotide and the domain is associated with the second oligonucleotide.7. The nanoparticle of wherein the domain comprises a polythymidine (polyT) sequence comprising more than one thymidine residue.8. The nanoparticle of wherein the domain comprises a polythymidine (polyT) sequence comprising two thymidine residues.9. The nanoparticle of wherein the domain comprises a polythymidine (polyT) sequence comprising two claim 1 , three claim 1 , four claim 1 , five claim 1 , six claim 1 , seven claim 1 , eight claim 1 , nine claim 1 , ten claim 1 , eleven claim 1 , twelve claim 1 , thirteen claim 1 , fourteen claim 1 , fifteen claim 1 , sixteen claim 1 , seventeen claim 1 , eighteen claim 1 , nineteen claim 1 , or twenty thymidine residues.10. The nanoparticle of wherein the domain comprises a phosphate polymer (C3 residue).11. The nanoparticle of wherein the domain comprises two or more phosphate polymers (C3 residues).12. A method of modulating cellular uptake ...

Подробнее
Номер записи: 33
18-07-2013 дата публикации

NOVEL SYNTHESIS OF 5-DEOXY-5'-FLUOROCYTIDINE COMPOUNDS

Номер: US20130184451A1
Автор: Chien Chungsun, Lin Ko-Chung
Принадлежит: PharmaEssentia Corp.

This invention relates to a process of synthesizing a β-nucleoside compound of formula (I): 2. The process of claim 1 , wherein the base is selected from the group consisting of pyridine claim 1 , immidazole claim 1 , ammonium claim 1 , monoalkylamine claim 1 , dialkylamine claim 1 , trialkylamine claim 1 , sodium carbonate claim 1 , and potassium carbonate.3. The process of claim 1 , wherein the solvent is acetone claim 1 , acetonitrile claim 1 , dimethylformamide claim 1 , ethyl acetate claim 1 , 1 claim 1 ,2-dichloroethane (DCE) claim 1 , dimethylacetamide (DMAC) claim 1 , dimethylsulfoxide (DMSO) claim 1 , tetrahydrofuran claim 1 , isopropyl acohol claim 1 , acetonitrile claim 1 , or nitromethane claim 1 , or a mixture of ACN/HO or acetone/HO.4. The process of claim 1 , wherein X is Cl claim 1 , 4-nitrophenoxy claim 1 , or N-succinimidyloxy.5. The process of claim 1 , wherein Ris alkyl.6. The process of claim 5 , wherein Ris n-pentyl.7. The process of claim 1 , wherein the base is pyridine or immidazole.8. The process of claim 6 , wherein X is Cl claim 6 , 4-nitrophenoxy claim 6 , or N-succinimidyloxy.9. The process of claim 8 , wherein the base is pyridine or immidazole.10. The process of claim 9 , wherein the solvent is acetone claim 9 , acetonitrile claim 9 , dimethylformamide claim 9 , ethyl acetate claim 9 , 1 claim 9 ,2-dichloroethane (DCE) claim 9 , dimethylacetamide (DMAC) claim 9 , dimethylsulfoxide (DMSO) claim 9 , tetrahydrofuran claim 9 , isopropyl acohol claim 9 , acetonitrile claim 9 , or nitromethane claim 9 , or a mixture of ACN/HO or acetone/HO.11. The process of claim 10 , wherein the solvent is DMF claim 10 , DMSO claim 10 , or DMAC.12. The process of claim 11 , wherein X is Cl.13. The process of claim 12 , where the base is pyridine.14. The process of claim 13 , wherein the reaction is carried out at a temperature of 50-100° C.15. The process of claim 14 , wherein the reaction is carried out at a temperature of 65-80° C.16. The process of ...

Подробнее
Номер записи: 34
18-07-2013 дата публикации

WATERLESS DEGUMMING SYSTEM

Номер: US20130184452A1
Автор: Dyas Michael, Lupien John C.
Принадлежит: Bastlab, LLC

A method and system for cleaning lignin and other gums from lignocellulosic fiber is disclosed. Lignocellulosic fiber is rapidly depressurized to a pressure lower than atmospheric pressure. The fiber is exposed to ionized air during the rapid depressurization. The fiber is then repressurized to a pressure equal to or greater than atmospheric pressure. 1. A method of stabilizing and cleaning lignocellulosic fiber comprising the steps of rapid depressurizing of the fiber to a pressure lower than atmospheric; andrapid repressurizing of the fiber to atmospheric pressure or greater.2. The method of claim 1 , wherein the fiber is exposed to variation in temperature as it is either depressurized or repressurized.3. The method of claim 2 , further comprising exposing the fiber to ionized air during the step of rapid depressurization.4. The method of claim 1 , further comprising exposing the fiber to ozone.5. A method of cleaning lignin and other gums from lignocellulosic fiber comprising the steps of:rapid depressurizing of the fiber to a pressure rower than atmospheric;exposing said fiber to ionized air during the step of rapid depressurization to vacuum; andrapid repressurizing of the fiber to atmospheric pressure or greater.6. The method of claim 5 , further comprising the step of exposing the fiber to a variation in temperature.7. A system for cleaning lignin and other gums from lignocellulosic fiber comprising:an ion generator;reaction chamber coupled to the ion chamber; anda vacuum draw down device coupled to the reaction chamber;wherein the reaction chamber is configured to hold a mass of lingnocellulosic fiber and expose the fiber to a range of pressures and temperatures.8. The system of claim 7 , wherein the reaction chamber is configured to hold the mass of lignocellulosic at a pressure below ambient pressure.9. The system of claim 8 , wherein the system is configured to contact the mass of lignocellulosic fiber with ionized air provided by the ion generator in ...

Подробнее
Номер записи: 35
25-07-2013 дата публикации

AFFINITY PURIFICATION OF RNA UNDER NATIVE CONDITIONS BASED ON THE LAMBDA BOXB/N PEPTIDE INTERACTION

Номер: US20130189757A1
Автор: Legault Pascale
Принадлежит: VALORISATION-RECHERCHE, LIMITED PARTNERSHIP

Reagents, methods, constructs and kits are described for immobilizing or purifying a target RNA of interest, based on the interaction of boxB RNA with a bacteriophage N peptide, which in turn is linked to an immobilizing moiety capable of binding to a solid support. 1. A construct for immobilizing a bacteriophage boxB-comprising RNA on a solid support , said construct comprising:a boxB RNA binding peptide;a peptide linker linked to the C-terminus of said bacteriophage N peptide; andan immobilizing moiety capable of binding to said solid support, wherein said immobilizing moiety is linked to said peptide linker.23-. (canceled)4. The construct of claim 1 , wherein said boxB RNA binding peptide is a bacteriophage N peptide.5. The construct of claim 4 , wherein said bacteriophage N peptide comprises a domain of formula I:{'br': None, 'sup': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14, 'X—X-A/S—X—X—R/K—X—X—X—R/K—R/K—X—X—X—X—X—X—X\u2003\u2003(I)'}wherein{'sup': '1', 'Xis any amino acid or is absent;'}{'sup': '2', 'Xis A, D, T or N;'}{'sup': '3', 'Xis Q, R or K;'}{'sup': '4', 'Xis A, T or S;'}{'sup': '5', 'Xis Y or R'}{'sup': '6', 'Xis R, K or H;'}{'sup': '7', 'Xis E or A;'}{'sup': '8', 'Xis any amino acid;'}{'sup': '9', 'Xis any amino acid;'}{'sup': '10', 'Xis any amino acid;'}{'sup': '11', 'Xis any amino acid;'}{'sup': '12', 'Xis any amino acid;'}{'sup': '13', 'Xis any amino acid; and'}{'sup': '14', 'Xis any amino acid.'}6. The construct of claim 5 , wherein{'sup': '1', 'Xis M or G'}{'sup': '8', 'Xis A or R;'}{'sup': '9', 'Xis E, K or M;'}{'sup': '10', 'Xis K, L or E;'}{'sup': '11', 'Xis Q, I, A, or R;'}{'sup': '12', 'Xis A or I;'}{'sup': '13', 'Xis Q, E or T; and/or'}{'sup': '14', 'Xis W, R or L.'}7. The construct of claim 6 , wherein{'sup': '1', 'Xis G;'}{'sup': '2', 'Xis N; and/or'}{'sup': '3', 'Xis K.'}8. The construct of claim 7 , wherein said domain is Met-Asp-Ala-Gln-Thr-Arg-Arg-Arg-Glu-Arg-Arg-Ala-Glu-Lys-Gln-Ala-Gln-Trp (SEQ ID NO:2); ...

Подробнее
Номер записи: 36
01-08-2013 дата публикации

METHOD FOR ACQUISITION OF SMALL RNA

Номер: US20130197206A1
Автор: Hirayasu Kazunari, Nishibu Takahiro
Принадлежит: WAKO PURE CHEMICAL INDUSTRIES, LTD.

The purpose of the present invention is to provide a method which is applicable to high throughput and by which small RNA can be obtained simply and efficiently. The present invention relates to a method for acquisition of small RNA, comprising contacting a carrier, in which a substance having affinity to small RNA-binding protein is immobilized on its surface, with a complex of the small RNA-binding protein and a small RNA (protein-RNA complex) to bind the protein-RNA complex to the aforementioned carrier, and releasing the small RNA by heating the carrier bound with the aforementioned protein-RNA complex at 70° C. to 100° C. in water or buffer solution of pH 3.0 to pH 8.0 1. A method for acquisition of small RNA , comprisingcontacting a carrier, in which a substance having affinity to small RNA-binding protein is immobilized on its surface, with a complex of the small RNA-binding protein and a small RNA (protein-RNA complex) to bind the protein-RNA complex to the aforementioned carrier, andreleasing the small RNA by heating the carrier bound with the aforementioned protein-RNA complex at 70° C. to 100° C. In water or buffer solution of pH 3.0 to pH 8.0.2. The method according to claim 1 , wherein after the protein-RNA complex is bound to the carrier claim 1 , and before heating claim 1 , the obtained carrier bound with protein-RNA complex is washed.3. The method according to claim 1 , wherein the carrier is heated in buffer solution.4. The method according to claim 1 , wherein the pH of the buffer solution is 4.5 to 7.0.5. The method according to claim 1 , wherein the buffer solution is citrate buffer solution claim 1 , Good's buffer solution or phosphate buffer solution.6. The method according to claim 1 , wherein the heating time is 30 seconds to 600 seconds.7. The method according to claim 1 , wherein the water or the buffer solution is the one containing RNA or DNA which does not comprise any nucleotide sequence of target RNA.8. The method according to claim 2 ...

Подробнее
Номер записи: 37
01-08-2013 дата публикации

MODIFIED NUCLEOTIDES

Номер: US20130197209A1
Автор: Bames Colin, Brennan Joseph, Liu Xiaohai, Milton John, Ruediger Silke, Smith Mark, Wu Xiaolin
Принадлежит: ILLUMINA CAMBRIDGE LIMITED

The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R′)2-O—R″, —C(R′)2-N(R″)2, —C(R′)2-N(H)R″, —C(R′)2-S—R″ and —C(R′)2-F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R′)2 represents an alkylidene group of formula ═C(R′″)2 wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R″ is exchanged for H or, where Z is —C(R′) 2-F, the F is exchanged for OH, SH or NH2, preferably OH, which intermediate dissociates under aqueous conditions to afford a molecule with a free 3′OH; with the proviso that where Z is —C(R′)2-S—R″, both R′ groups are not H. 118-. (canceled)19. A method of converting a compound of formula R—O-allyl , RN(allyl) , RNH(allyl) , RN(allyl)or R—S-allyl to a corresponding compound in which the allyl group is removed and replaced by hydrogen , said method comprising the steps of reacting a compound of formula R—O-allyl , RN(allyl) , RNH(allyl) , RN(allyl)or R—S-allyl in aqueous solution with a transition metal comprising a transition metal and one or more bands selected from the group comprising water-soluble phosphine and water-soluble nitrogen-containing phosphine ligands , wherein the or each R is a water-soluble biological molecule , which is part of a nucleoside , a nucleotide or polynucleotide molecule , wherein said nucleoside , nucleotide or polynucleotide further comprises a ...

Подробнее
Номер записи: 38
01-08-2013 дата публикации

Low Temperature Chlorination of Carbohydrates

Номер: US20130197213A1
Автор: Erickson William Randal, Fields Stephen Craig
Принадлежит: LEXINGTON PHARMACEUTICALS LABORATORIES, LLC

Disclosed is a method of chlorinating a carbohydrate or derivative thereof, for example, a sucrose-6-ester at the 4,1′, and 6′ positions, with irreversible removal of HCl formed during the reaction to form the chlorinated carbohydrate or derivative thereof, for example, a 4,1′,6′-trichloro-4,1′,6′-trideoxy-6-O-ester of galactosucrose (TGS-6E). The irreversible removal of HCl can be carried out by an irreversible physical process and/or an irreversible chemical process. Sucralose, an artificial sweetener, can be prepared by deesterification of the TGS-6E. The chlorination reaction takes place at low temperatures and the desired chlorinated product is obtained in high yields and in high purities. 1. A method for chlorinating a carbohydrate or a derivative thereof comprising reacting the carbohydrate or derivative thereof with a chlorinating agent and irreversibly removing during chlorination the hydrogen chloride produced by the reaction of the chlorinating agent with the carbohydrate or derivative thereof.2. The method of claim 1 , wherein the carbohydrate or derivative thereof is a sugar or derivative thereof.3. The method of claim 2 , wherein the sugar derivative is a sugar ester.4. The method of claim 3 , wherein the sugar ester is a sucrose-6-ester.5. The method of claim 4 , wherein the chlorinated product obtained is 4 claim 4 ,1′ claim 4 ,6′-trichloro-4 claim 4 ,1′ claim 4 ,6′-trideoxy-6-O-ester of galactosucrose (TGS-6E).6. The method of claim 1 , wherein the chlorinating agent is an acid chloride.7. The method of claim 6 , wherein the chlorinating agent is a Vilsmeier Reagent having the formula: [XYC═NR]Cl claim 6 , wherein X is hydrogen claim 6 , aryl claim 6 , or alkyl claim 6 , wherein the aryl or alkyl is optionally substituted with a halogen claim 6 , alkoxy claim 6 , thioalkoxy claim 6 , amido claim 6 , or cyano; Y is a leaving group; and R is hydrogen or alkyl which is optionally substituted with halogen claim 6 , alkoxy claim 6 , thioalkoxy claim 6 , ...

Подробнее
Номер записи: 39
01-08-2013 дата публикации

Chlorination of Carbohydrates and Carbohydrate Derivatives

Номер: US20130197215A1
Автор: Erickson William Randal, Fields Stephen Craig
Принадлежит:

Disclosed is a method for chlorinating a carbohydrate or a derivative thereof to produce a polychlorinated carbohydrate or a derivative thereof, such as sucralose, the method involves (i) reacting the carbohydrate or derivative thereof with a chlorinating agent to obtain a reaction mixture comprising said polychlorinated carbohydrate or derivative thereof and at least one under-chlorinated carbohydrate or derivative thereof, (ii) returning the at least one under-chlorinated carbohydrate or derivative thereof to a chlorinating step and further chlorinating the at least one under-chlorinated carbohydrate or derivative thereof to obtain the desired polychlorinated carbohydrate or derivative thereof; and (iii) optionally repeating steps (i) and (ii) “n” times where n≧1. The polychlorinated carbohydrate or a derivative thereof is obtained in high yields. 1. A method for chlorinating a carbohydrate or a derivative thereof , wherein said carbohydrate or derivative thereof has two or more hydroxyl groups , to produce a polychlorinated carbohydrate or a derivative thereof , said polychlorinated carbohydrate or a derivative thereof having a desired number of chlorine atoms replacing two or more of the hydroxyl groups at desired locations in its molecular structure , the method comprising:(i) reacting the carbohydrate or derivative thereof with a chlorinating agent to obtain a reaction mixture comprising said polychlorinated carbohydrate or derivative thereof and at least one under-chlorinated carbohydrate or derivative thereof;(ii) returning the at least one under-chlorinated carbohydrate or derivative thereof to a chlorinating step and further chlorinating the at least one under-chlorinated carbohydrate or derivative thereof to obtain the desired polychlorinated carbohydrate or derivative thereof; and(iii) optionally repeating steps (i) and (ii) “n” times where n≧1.2. The method of claim 1 , further comprising:(iv) quenching at least a portion of the reaction mixture from ...

Подробнее
Номер записи: 40
01-08-2013 дата публикации

Device And Method For Extracting Active Principles From Natural Sources, Using A Counter-Flow Extractor Assited By A Sound Transduction System

Номер: US20130197216A1
Автор: ALARCON CAMACHO John Gabriel, Cares Pacheco María Graciela, Gaete Garreton Luis Francisco Javier, SAINZ LOBO Javier Ignacio, Vargas Hernández Yolanda del Pilar
Принадлежит: NATURAL RESPONSES S.A.

The invention relates to a device and method for extracting active principles from natural sources, using a counter-flow extractor assisted by a sound transduction system, which allows a cavitation sound field to be applied in the zone containing the material formed by the raw material of the natural product and a solvent extraction medium. According to the invention, the device () comprises: an inclined casing () containing a helical screw conveyor () having a plurality of blades (), said casing including a lower end () and an upper end (); a hopper () for introducing the material, which is disposed on top of the lower end () such that it is inclined at an angle # in relation to the surface of the casing (), said feed hopper () including a second helical screw conveyor (); an outlet hopper () for releasing the treated material, which hopper is located at the upper end () of the casing (); a first load line () for loading the solvent extraction medium, which load line is located at the upper end (); a discharge line () for discharging the liquid extract, which discharge line is located at the lower end () and is provided with a screen () that filters the liquid extract; and a sound transduction system () for producing ultrasound, which is located at the lower end () on a surface portion (). The method comprises the following steps: (a) preparing the raw material; (b) supplying the product and the solvent to the device, in counter-flow mode; (c) applying a sound field to the product together with the solvent; (d) extracting the product with the extraction liquid, in counter-flow mode; and (e) collecting the liquid extract and the depleted material. 1. An apparatus for the extraction of active principles from natural sources using an extractor on countercurrent assisted by an acoustic transducer system , which allows the application of an cavitative acoustic field in the area flooded with the material comprised of the raw material of the natural product and a solvent ...

Подробнее
Номер записи: 41
08-08-2013 дата публикации

Method for Isolation of Nucleic Acids and a Kit Thereof

Номер: US20130203150A1
Автор: Chandrasekhar Bhaskaran Nair, Mitchell Preetham Pinto, MULAKKAPURATH NARAYANAN Manoj, Phani Kumar Pullela, Pillarisetti Venkata Subbarao, Santhosh Kumar Gandhavalla
Принадлежит: Bigtec Pvt Ltd

The present disclosure provides a method to isolate natural & artificial nucleic acids like deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide nucleic acid (PNA) from a solid or liquid sample using cotton. The cotton packed is such that, a solution containing nucleic acids passes through it and the nucleic acids in solution are bound to the cotton in a medium optimal for binding. The nucleic acids are bound to cotton in such a way that, the bound nucleic acids can withstand multiple washes with liquid comprising water and gets eluted in an aqueous buffer, with which eluted nucleic acids can be directly used for amplification using PCR or for any other biochemical or molecular biology needs.

Подробнее
Номер записи: 42
29-08-2013 дата публикации

Method of Preparing a Nucleic Acid Library

Номер: US20130225452A1
Автор: Eckhardt Allen E., Pollack Michael G., Rouse Jeremy, Thwar Prasanna
Принадлежит: ADVANCED LIQUID LOGIC INC

A method of preparing a nucleic acid library in droplets in contact with oil, including: (a) blunt-ending nucleic acid fragments in a droplet in the oil to yield blunt-ended nucleic acid fragments; 1. A method of purifying nucleic acid fragments in a droplet in contact with oil , comprising conducting the following , steps in contact with oil:(a) merging a droplet comprising the nucleic acid fragments with a bead droplet comprising solid phase reversible immobilization beads to capture the nucleic acid fragments;(b) washing the solid phase reversible immobilization beads using a droplet-based merge-and-split wash protocol using wash buffer droplets to yield a droplet comprising washed beads comprising the nucleic acid fragments;(c) merging a droplet comprising washed beads with an elution buffer droplet to yield an elution droplet comprising eluted blunt-ended/phosphorylated nucleic acid fragments; and(d) separating the nucleic acid fragments from the solid phase reversible immobilization beads to yield a droplet comprising the purified nucleic acid fragments in the oil.2. The method of any of wherein the wash buffer droplets comprise droplets that consist essentially of an aqueous buffer.3. The method of wherein the aqueous buffer consists essentially of a binding buffer.4. The method of wherein the aqueous buffer is substantially lacking in organic solvents.5. The method of wherein the aqueous buffer comprises no more than about 10% organic solvent.6. The method of wherein the aqueous buffer is substantially lacking in ethanol.7. The method of wherein the aqueous buffer comprises no more than about 10% ethanol.8. The method of wherein the wash buffer droplets comprise droplets comprising at least about 25% organic solvent.9. The method of wherein the wash buffer droplets comprise droplets comprising at least about 50% organic solvent.10. The method of wherein the wash buffer droplets comprise droplets comprising at least about 50% organic solvent.11. The method ...

Подробнее
Номер записи: 43
29-08-2013 дата публикации

METHOD OF ISOLATING PURIFIED RNA WITH REDUCED DNA CONTAMINATIONS

Номер: US20130225801A1
Автор: Christoffel Gabriele
Принадлежит:

The present invention pertains to a method of isolating RNA from a sample comprising RNA, and DNA, comprising: a) adding an acidic denaturing composition comprising a chaotropic agent and phenol to the sample; b) adding a water-insoluble organic solvent and separating the resulting phases thereby forming a multi-phase mixture comprising an aqueous phase, optionally an interphase and an organic phase, wherein the RNA is concentrated in said aqueous phase and DNA and proteins are concentrated in said organic phase and/or in said interphase; and c) isolating said RNA from said aqueous phase, wherein at least one cationic detergent is added before separating the phases. It was found that the addition of at least one cationic detergent considerably reduces the amount of DNA in the aqueous, RNA containing phase. Therefore, the present invention allows to easily isolate pure RNA which comprises considerably less DNA contaminations. 115.-. (canceled)16. A method of isolating at least RNA from a sample comprising RNA and DNA , comprising: i) an acidic denaturing composition comprising a chaotropic agent and phenol,', 'ii) at least one cationic detergent, and', 'iii) a water-insoluble organic solvent;, 'a) to a sample comprising RNA and DNA, addingb) separating the phases of the mixture obtained in step a) to form a multi-phase mixture comprising an aqueous phase, optionally an interphase, and an organic phase, wherein the RNA is concentrated in said aqueous phase and DNA is concentrated in said organic phase and/or in said interphase; andc) isolating said RNA from said aqueous phase.17. The method of claim 16 , wherein step a) i) further comprises homogenising the sample in the acidic denaturing composition.18. The method of claim 16 , wherein the at least one cationic detergent is added before claim 16 , at the same time claim 16 , or after the acidic denaturing composition is added to the sample.19. The method of claim 16 , wherein the at least one cationic detergent is ...

Подробнее
Номер записи: 44
05-09-2013 дата публикации

Method for preparing albiflorin and paeoniflorin

Номер: US20130231469A1
Автор: Zuoguang Zhang
Принадлежит: Individual

The present invention discloses a method for preparing high purity paeoniflorin and albiflorin simultaneously comprising: extraction the raw material Paeonia Lactiflora by percolation or heating reflux to obtain the Paeonia Lactiflora extract solution, then purification by macroporous absorption resin, alumina column and silica gel column in turn to obtain high purity paeoniflorin and albiflorin. The preparation method of the invention can provide high purity paeoniflorin and albiflorin with low price and energy-consumption by the identical procedure. The process is simple. The purification efficacy is high and the purification time is short.

Подробнее
Номер записи: 45
12-09-2013 дата публикации

METHOD AND DEVICE FOR ISOLATING AND PURIFYING DOUBLE-STRANDED NUCLEIC ACIDS

Номер: US20130237699A1
Автор: Singer Thorsten, Wedler Holger
Принадлежит: QIAGEN GmbH

The invention relates to a chromatographic device for isolating and/or purifying double-stranded nucleic acids, preferably double-stranded DNA, from a mixture of such nucleic acids with single-stranded nucleic acids, oligonucleotides, mononucleotides, salts and/or other such impurities. The invention also relates to a method for chromatographically isolating and/or purifying same, and to a kit for this purpose. 115.-. (canceled)16. A chromatographic device for isolating and/or purifying double-stranded nucleic acids , comprising:(1) a base body,(2) at least one cavity within the base body, which cavity is provided with an inlet and an outlet, and (a) at least one porous chromatography resin that acts as a size-exclusion chromatography medium, and', '(b) immobilized metal ions., '(3) a stationary phase situated in the cavity, wherein the stationary phase comprises17. The device of claim 16 , wherein the double-stranded nucleic acids are double-stranded DNA.18. The device of claim 16 , further comprising at least one of the following features: a porous filter claim 16 , a porous frit or a membrane that is arranged between the outlet of the cavity and the stationary phase and retains the stationary phase in the cavity claim 16 , at least one closure device for closing the inlet and/or the outlet of the cavity claim 16 , and at least one collection vessel for collecting the mobile phase (eluate) emerging from the outlet after elution has occurred.19. The device of claim 16 , wherein the immobilized metal ions are divalent claim 16 , trivalent or tetravalent metal cations or mixtures thereof.20. The device of claim 19 , wherein the immobilized metal ions are selected from the group consisting of Zn claim 19 , Co claim 19 , Cu claim 19 , Ni claim 19 , Fe claim 19 , Mn claim 19 , Al claim 19 , Co claim 19 , Ga and Zr claim 19 , and a combination thereof.21. The device of claim 19 , wherein the immobilized metal ions are at least one divalent metal cation selected from the ...

Подробнее
Номер записи: 46
19-09-2013 дата публикации

METHODS AND COMPOSITIONS FOR ISOLATING SMALL RNA MOLECULES

Номер: US20130245245A1
Автор: Conrad Richard
Принадлежит: LIFE TECHNOLOGIES CORPORATION

The present invention concerns the use of methods and compositions for the isolation of small RNA molecules (100 nucleotides or fewer), such as microRNA and siRNA molecules. Such molecules are routinely lost in commonly used isolation procedures and therefore the present invention allows for a much higher level of enrichment or isolation of these small RNA molecules. 1. A method for isolating small RNA molecules from cells comprising:a) lysing the cells with a lysing solution to produce a lysate;b) adding an alcohol solution to the lysate;c) applying the lysate to a solid support;d) eluting small RNA molecules from the solid support; and,e) using or characterizing the small RNA molecules.25-. (canceled)6. The method of claim 1 , wherein the lysing solution comprises a chaotropic agent or detergent.7. The method of claim 6 , wherein the lysing solution comprises a chaotropic agent.814-. (canceled)15. The method of claim 1 , further comprising extracting small RNA molecules from the lysate with an extraction solution comprising an organic solvent prior to applying the lysate to the solid support.1617-. (canceled)18. The method of claim 1 , wherein the amount of alcohol solution added to the lysate makes the lysate about 20% to about 70% alcohol.1926-. (canceled)27. The method of claim 1 , wherein the small RNA molecules are eluted from the solid support with a low-ionic-strength solution.28. The method of claim 27 , wherein the ionic solution comprises up to 10 mM salt.29. The method of claim 1 , wherein the solid support is a mineral support or polymer support.30. The method of claim 29 , wherein the mineral support or polymer support is a column comprising silica.3132-. (canceled)33. The method of claim 30 , wherein the silica is glass fiber.3438-. (canceled)39. The method of claim 1 , wherein the small RNA molecules have at most 100 nucleotides or fewer.40. The method of claim 39 , wherein the small RNA molecules have at most 70 nucleotides or fewer.41. The method ...

Подробнее
Номер записи: 47
26-09-2013 дата публикации

Method for Separating and Detecting an Analyte

Номер: US20130252249A1
Автор: Belz Renato, Gisler Andreas, Huesler Robert, Knobel Rolf, Thalmann Christian
Принадлежит:

A method for separating and analyzing an analyte is provided which comprises, in a first position, transferring a liquid sample to a multiwell plate with a pipette tip, replacing the tips in the tip rack in the same position, and re-using the pipette tips for aspirating and dispensing liquid. 1. A method for isolating and analyzing an analyte that may be present in a fluid sample , the method comprising the automated steps of:a) transferring said fluid sample from a sample vessel to a processing vessel with a pipette tip of a first type;b) combining together a solid support material and said fluid sample in a well of said processing vessel for a period of time and under conditions sufficient to permit said analyte to be immobilized on the solid support material;c) isolating the solid support material from other material present in the fluid sample in a separation station; andd) purifying the analyte in the separation station by separating the fluid sample from the solid support material and washing the materials one or more times with a wash buffer;wherein said pipette tip of a first type used in step a) is re-used after step a), and wherein said pipette tip of a first type is stored in a rack comprising pipette tips of a first type and pipette tips of a second type.2. The method of claim 1 , wherein step a) comprises:a1) engaging pipette tips of a first type which are held in a rack in a first position with a first process head;a2) transferring said fluid sample from a sample vessel to a processing vessel with pipette tips of a first type engaged to a first process head;a3) placing said pipette tips in said rack and disengaging said pipette tips from said process head;a4) transporting said rack comprising said pipette tips and said processing vessel to second positions; anda5) engaging said pipette tips of a first type which are held in said rack with a second process head in said second position.3. The method of claim 1 , wherein said analyte is a nucleic acid.4. ...

Подробнее
Номер записи: 48
26-09-2013 дата публикации

2'-O-MODIFIED RNA

Номер: US20130253178A1
Автор: Arai Kouichiro, Shimizu Mamoru, Wada Takeshi
Принадлежит:

[Problem] 2. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': '4', 'wherein R′ to Rmay be identical or different, and each represents a hydrogen atom, a methyl group or an ethyl group,'}{'sup': 5', '6, 'sub': '1-3', 'Rand Rmay be identical or different, and each represents a hydrogen atom, a halogen atom, or a Chaloalkyl group, and'}{'sup': '7', 'Rrepresents a halogen atom.'}3. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': 1', '4, 'wherein all of Rto Rrepresent a hydrogen atom,'}{'sup': 5', '6, 'Rand Rmay be identical or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or a bromine atom, and'}{'sup': '7', 'Rrepresents a fluorine atom, a chlorine atom or a bromine atom.'}4. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': 1', '5, 'wherein all of Rto Rrepresent a hydrogen atom,'}{'sup': '6', 'Rrepresents a hydrogen atom, a fluorine atom or a chlorine atom, and'}{'sup': '7', 'Rrepresents a fluorine atom or a chlorine atom.'}5. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': 1', '5, 'wherein all of Rto Rrepresent a hydrogen atom,'}{'sup': '6', 'Rrepresents a hydrogen atom, or a chlorine atom, and'}{'sup': '7', 'Rrepresents a chlorine atom.'}6. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 , which is2′-O-(2-chloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,2′-O-(2,2-dichloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,2′-O-( ...

Подробнее
Номер записи: 49
03-10-2013 дата публикации

FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE

Номер: US20130261014A1
Автор: Lukhtanov Eugeny A., Scarr Noah, Vorobiev Alexei
Принадлежит:

3-alkynyl inosine analogs and their uses as universal bases are provided. The inosine analogues can be incorporated into nucleic acid primers and probes. They do not significantly destabilize nucleic acid duplexes. As a result, the novel nucleic acid primers and probes incorporating the inosine analogues can be used in a variety of methods. The analogs function unexpectedly well as universal bases. Not only do they stabilize duplexes substantially more than hypoxanthine opposite A, C, T, and G but they are also recognized in primers by polymerases, allowing efficient amplification. 2. The method of claim 1 , wherein the mismatched duplex has substantially the same stability as a corresponding duplex with a natural base in place of 3-alkynyl-1H-pyrazolo[3 claim 1 ,4-d]pyrimidin-4(5H)-one analogue.3. The method of claim 1 , wherein the mismatched base is A claim 1 , T or C.4. The method of wherein the mismatched base is G.5. The method of wherein the 3-alkynyl-1H-pyrazolo[3 claim 1 ,4-d]pyrimidin-4(5H)-one analogue is substituted with pyrene.6. A method for monitoring of polynucleotide amplification of a set of target nucleic acid sequences claim 1 , comprising:(a) providing a mixture comprising a sample containing the target nucleic acid sequences, one or more than one oligonucleotide primers substantially complementary to a portion of the target nucleic acid sequences, a polymerizing enzyme, nucleotide substrates, and a detectable nucleic acid oligomer probe of between 5 and 100 bases,wherein said detectable nucleic acid oligomer probe has a backbone component selected from the group consisting of a sugar phosphate backbone, a modified sugar phosphate backbone, a locked nucleic acid backbone, a peptidic backbone, or a variant thereof,wherein said nucleic acid oligomer probe has a sequence substantially complementary to a probe region of the target nucleic acid sequence,wherein said nucleic acid oligomer probe comprises a fluorophore,wherein at least one of said ...

Подробнее
Номер записи: 50
03-10-2013 дата публикации

EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM

Номер: US20130261291A1
Автор: MA Chun, NADJI Sourena, OHRR Kevin K., PATEL Payal Parth
Принадлежит: Reliable Biopharmaceutical Corporation

The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds. 118-. (canceled)20. The process of claim 19 , further comprising converting the monosaccharide AMod3 to Fondaparinux sodium. This application claims the benefit of U.S. Provisional Patent Application No. 61/256,855, filed Oct. 30, 2009, which is hereby incorporated by reference. This application incorporates by reference U.S. Provisional Application Ser. No. 61/230,557, filed Jul. 31, 2009 and U.S. patent application Ser. No. 12/847,719, filed Jul. 30, 2010.The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.In U.S. Pat. No. 7,468,358, Fondaparinux sodium is described as the “only anticoagulant thought to be completely free of risk from HIT-2 induction.” The biochemical and pharmacologic rationale for the development of a heparin pentasaccharide in 86(1). 1-36, 1997 by Walenga et al. cited the recently approved synthetic pentasaccharide Factor Xa inhibitor Fondaparinux sodium. Fondaparinux has also been described in Walenga et al., , Vol. 11, 397-407, 2002 and Bauer, & , Vol. 17, No. 1, 89-104, 2004.Fondaparinux sodium is a linear octasulfated pentasaccharide (oligosaccharide with five monosaccharide units) molecule having five sulfate esters on oxygen (O-sulfated moieties) and three sulfates on a nitrogen (N-sulfated moieties). In addition, Fondaparinux contains five hydroxyl groups in the molecule that are not sulfated and two sodium carboxylates. Out of five saccharides, there are three glucosamine derivatives and ...

Подробнее
Номер записи: 51
10-10-2013 дата публикации

TRANSCRIPTOME IN VIVO ANALYSIS

Номер: US20130267678A1
Автор: Dmochowski Ivan, Eberwine James, Lovatt Ditte, Richards Julia, Ruble Brittani
Принадлежит: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Provided are compositions and methods that permit a hybrid nucleic acid-peptide molecule to enter a cell and when specifically activated within the cell, the molecule anneals to endogenous cellular RNA and permits the isolation of the RNA. 1. A hybrid nucleic acid-peptide molecule comprising:a) a first, second, and third oligomer, wherein the first oligomer is linked to the second oligomer through a first photocleavable linker and the second oligomer is linked to the third oligomer through a second photocleavable linker;b) a label for isolating nucleic acids;c) a peptide moiety comprising a cell penetrating peptide (CPP).2. The molecule of claim 1 , wherein the first oligomer is at least an 18mer fluoro claim 1 , wherein the second oligomer is at least a poly-A 7mer claim 1 , and the third oligomer is at least a poly-A 7mer.3. The molecule of claim 1 , wherein the first oligomer is at least an 18mer 2′-fluoro claim 1 , wherein the second oligomer is at least a poly-A 14mer claim 1 , and the third oligomer is at least a poly-A 14mer.4. The molecule of claim 1 , wherein the molecule is caged in the absence of cleavage of the photocleavable linker.5. The molecule of claim 1 , wherein the molecule is uncaged in the presence of cleavage of the photocleavable linker.6. The molecule of claim 1 , wherein the label is linked to the first oligomer.7. The molecule of claim 1 , wherein the label is biotin.8. The molecule of claim 1 , wherein the CPP is linked to the third oligomer.9. A method of isolating cellular RNA in a live cell claim 1 , the method comprising the steps of: introducing the molecule of into a cell claim 1 , activating the cell under conditions suitable for binding of the nucleic acid portion of the hybrid molecule to cellular RNA wherein the activation cleaves the photocleavable linkers in the molecule claim 1 , allowing the formation of a hybridized nucleic acid molecule/cellular RNA complex claim 1 , and isolating the hybridized nucleic acid molecule/ ...

Подробнее
Номер записи: 52
10-10-2013 дата публикации

PROCEDURE FOR THE PURIFICATION OF TIACUMICIN B

Номер: US20130267692A1
Автор: Fonte Piera, Lazzari Giovanni
Принадлежит: OLON S.p.A.

The present invention relates to an improved process for the purification of tiacumicin B. Specifically, the invention relates to a simplified, optimised process for the purification of tiacumicin B from a fermentation broth, using chromatography techniques. In particular, the invention relates to a method for purifying tiacumicin B which comprises subjecting a liquid containing tiacumicin B to at least one hydrophobic interaction chromatography step. 1. A process for purifying tiacumicin B comprising subjecting a liquid containing tiacumicin B to at least one hydrophobic interaction chromatography step.2. The process according to wherein the hydrophobic interaction chromatography uses a styrene-divinylbenzene resin.3. The process according to wherein the hydrophobic interaction chromatography uses a styrene-divinylbenzene resin selected from the group consisting of HP20 claim 2 , HP21 claim 2 , HP20SS claim 2 , SP20 claim 2 , SP2OSS claim 2 , SP825 claim 2 , SP850 claim 2 , SP207 claim 2 , XAD16 claim 2 , XAD1600 and XAD18.4. The process according to wherein the resin is HP20SS.5. The process according to wherein the hydrophobic interaction chromatography comprises the following steps:a) loading the liquid containing tiacumicin B at a pH ranging from 2.0 to 8.0 onto the hydrophobic interaction resin;b) eluting the impurities from the hydrophobic interaction resin with a mixture consisting of water and an organic solvent selected from methanol, ethanol, acetonitrile, acetone, THF or a mixture thereof at a pH ranging from 2.0 to 8.0;c) eluting tiacumicin B from the hydrophobic interaction resin with a mixture consisting of water and an organic solvent selected from methanol, ethanol, acetonitrile, acetone, THF or a mixture thereof at a pH ranging from 2.0 to 8.0;6. The process according to wherein the liquid containing tiacumicin B is loaded at a pH ranging from 2.5 to 6.5 onto the hydrophobic interaction resin.7. The process according to wherein the pH of the eluent ...

Подробнее
Номер записи: 53
10-10-2013 дата публикации

OLIGONUCLEOTIDE WITH PROTECTED BASE

Номер: US20130267697A1
Автор: HIRAI Kunihiro, KATAYAMA Satoshi, NAKAYA Ryotaro, TAKAHASHI Daisuke, TORII Takayoshi
Принадлежит:

The present invention provides a protected nucleotide for elongation, which can be purified efficiently and in a high yield by a liquid-liquid extraction operation, and can achieve an oligonucleotide production method by a phosphoramidite method. 2. The oligonucleotide comprising a protected base of according to claim 1 , wherein q is 0.4. The oligonucleotide comprising a protected base according to claim 3 , wherein R claim 3 , R claim 3 , Rin the number of l claim 3 , Rand Rare each independently a branched chain alkyl group or branched chain alkenyl group selected from the group consisting of a 2 claim 3 ,6 claim 3 ,10 claim 3 ,14-tetramethylpentadecyl group claim 3 , a 2 claim 3 ,6 claim 3 ,10-trimethylundecyl group claim 3 , a 2 claim 3 ,2 claim 3 ,4 claim 3 ,8 claim 3 ,10 claim 3 ,10-hexamethyl-5-undecyl group claim 3 , a 2 claim 3 ,6 claim 3 ,10-trimethylundeca-1 claim 3 ,5 claim 3 ,9-trienyl group claim 3 , a 2 claim 3 ,6-dimethylheptyl group claim 3 , a 2 claim 3 ,6-dimethylhept-5-enyl group claim 3 , a 2 claim 3 ,6-dimethylhepta-1 claim 3 ,5-dienyl group claim 3 , a 9-nonadecyl group claim 3 , a 12-methyltridecyl group claim 3 , an 11-methyltridecyl group claim 3 , an 11-methyldodecyl group claim 3 , a 10-methylundecyl group claim 3 , an 8-heptadecyl group claim 3 , a 7-pentadecyl group claim 3 , a 7-methyloctyl group claim 3 , a 3-methyloctyl group claim 3 , a 3 claim 3 ,7-dimethyloctyl group claim 3 , a 3-methylheptyl group claim 3 , a 3-ethylheptyl group claim 3 , a 5-undecyl group claim 3 , a 2-heptyl group claim 3 , a 2-methyl-2-hexyl group claim 3 , a 2-hexyl group claim 3 , a 3-heptyl group claim 3 , a 4-heptyl group claim 3 , a 4-methyl-pentyl group claim 3 , a 3-methyl-pentyl group claim 3 , and a 2 claim 3 ,4 claim 3 ,4-trimethylpentyl group; or a straight chain alkyl group selected from the group consisting of a tetradecyl group claim 3 , a tridecyl group claim 3 , a dodecyl group claim 3 , an undecyl group claim 3 , a decyl group claim 3 , a ...

Подробнее
Номер записи: 54
17-10-2013 дата публикации

TRISACCHARIDE DERIVATES, AND THEIR USE AS ADJUVANTS

Номер: US20130273082A1
Автор: Hof Robert Patrick, Kriek Maria Aldegonda Jacoba, Schaaper Wilhelmus Martinus Maria, Schenkelaars Everardus Joannes Peter Maria, Turkstra Jouwert Anne, Van Bree Johannes Gernardus Mathias Marie
Принадлежит: IMMUNOVO B.V.

The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions. 138-. (canceled)39. An adjuvant composition comprising:a trisaccharide derivate as the adjuvant, which derivate comprises a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups; andat least one of a pharmaceutical acceptable excipient and diluent.40. The adjuvant according to claim 39 , wherein the substituted trisaccharide core is derived from raffinose claim 39 , melezitose claim 39 , maltotriose claim 39 , nigerotriose claim 39 , maltotriulose or kestose claim 39 , preferably raffinose claim 39 , melezitose or maltotriose claim 39 , most preferably raffinose or maltotriose.41. The adjuvant according to claim 39 , wherein the substituted trisaccharide core comprises one or two sulphate ester or phosphate ester groups as anionic groups.42. The adjuvant according to claim 41 , wherein the anionic group is a sulphate ester.43. The adjuvant according to claim 39 , wherein the fatty acid ester group is an ester of a straight claim 39 , branched claim 39 , saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms.44. The adjuvant according to claim 39 , wherein the fatty acid ester is the ester of lauric acid claim 39 , myristic acid claim 39 , palmitic acid claim 39 , stearic acid or arachidic acid.45. The adjuvant according to claim 39 , wherein the fatty acid ester groups of the substituted trisaccharide core are all identical.46. The adjuvant according ...

Подробнее
Номер записи: 55
17-10-2013 дата публикации

HIGHLY SOLUBLE REBAUDISIDE D

Номер: US20130274351A1
Автор: MARKOSYAN Avetik, PURKAYASTHA Siddhartha
Принадлежит:

The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from Bertoni plant extract, more particularly Rebaudioside D. Obtained highly soluble compositions are useful as non-caloric sweeteners or in combination with sugar or high intensity sweeteners in edible and chewable compositions such as beverages, confectionaries, bakery products, chewing gums and the like. 1. A method of preparing a highly soluble steviol glycoside , comprising the steps of:a. providing a highly purified steviol glycoside;b. dissolving the highly purified steviol glycoside in a solvent selected from the group consisting of water or aqueous alcohol to make a solution;c. drying the solution to obtain the highly soluble steviol glycoside.2. The method of claim 1 , wherein the steviol glycoside is selected from the group consisting of Rebaudioside A claim 1 , Rebaudioside B claim 1 , Rebaudioside C claim 1 , Rebaudioside D claim 1 , Rebaudioside E claim 1 , Rebaudioside F claim 1 , Stevioside claim 1 , Dulcoside A claim 1 , and combinations thereof.3. The method of wherein the highly purified steviol glycoside comprises Rebaudioside D.4. The method of wherein an alcohol content of the aqueous alcohol is about 0.1-100% (vol/vol) claim 1 , preferably about 20-70% (vol/vol) claim 1 , and more preferably about 30-50% (vol/vol) claim 1 , and a ratio of aqueous alcohol to dissolved steviol glycoside solids (vol/wt) is about 5:1 to about 10:1.5. The method of wherein drying is performed by a technique capable of yielding materials with amorphous polymorphic forms.6. The method of claim 1 , wherein the highly soluble steviol glycoside is in an amorphous powder form.7. The method of claim 1 , additionally comprising the step of blending the highly purified steviol glycoside with a polyol to form a blend claim 1 , and the dissolving step (b) comprises dissolving the blend in the solvent.8. The method of claim 7 , wherein the highly purified ...

Подробнее
Номер записи: 56
17-10-2013 дата публикации

METHODS FOR ISOLATING CRYSTALLINE FORM I OF 5-AZACYTIDINE

Номер: US20130274459A1
Автор: Blumbergs Peter, Ionescu Dumitru, Silvey Gary L.
Принадлежит:

The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: 136-. (canceled)37. A method for isolating crystalline Form I of 5-azacytidine substantially free of other forms , the method comprising:recrystallizing 5-azacytidine from a solvent mixture comprising dimethylsulfoxide and isopropyl alcohol; andisolating the recrystallized 5-azacytidine.38. A method for isolating crystalline Form I of 5-azacytidine substantially free of other forms , the method comprising:recrystallizing 5-azacytidine from a solvent mixture comprising dimethylsulfoxide and 1-propanol; andisolating the recrystallized 5-azacytidine.39. A method for isolating crystalline Form I of 5-azacytidine substantially free of other forms , the method comprising:recrystallizing 5-azacytidine from a solvent mixture comprising dimethylsulfoxide and methanol by seeding said solvent mixture with Form I of 5-azacytidine; and isolating the recrystallized 5-azacytidine. The invention relates to the isolation of crystalline polymorphic Form I of 5-azacytidine (also known as azacitidine and 4-amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one). 5-azacytidine may be used in the treatment of disease, including the treatment of myelodysplastic syndromes (MDS).Polymorphs exist as two or more crystalline phases that have different arrangements and/or different conformations of the molecule in a crystal lattice. When a solvent molecule(s) is contained within the crystal lattice the resulting crystal is called a pseudopolymorph, or solvate. If the solvent molecule(s) within the crystal structure is a water molecule, then the pseudopolymorph/solvate is called a hydrate. The polymorphic and pseudopolymorphic solids display different physical properties, including those due to packing, and various thermodynamic, spectroscopic, interfacial and mechanical properties (See H. Brittain, Polymorphism in Pharmaceutical Solids, ...

Подробнее
Номер записи: 57
24-10-2013 дата публикации

METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS

Номер: US20130281686A1
Автор: "Clarke Michael ONeil Hanrahan", Cho Aesop, Wolckenhauer Scott Alan
Принадлежит: Gilead Sciences, Inc.

Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: 8. The method of wherein Ris H claim 1 , halogen claim 1 , optionally substituted (C-C)alkyl claim 1 , optionally substituted (C-C)alkenyl or optionally substituted (C-C)alkynyl.9. The method of wherein Ris H claim 8 , CHor F.10. The method of wherein each R claim 1 , Rand Ris H.11. The method of wherein one of Ror Ris H and the other of Ror Ris optionally substituted (C-C)alkyl.12. The method of wherein Ris optionally substituted (C-C)alkyl.13. The method of wherein Ris NRRor OR.14. The method of wherein Ris H or NRR.15. The method of wherein when Ror Ris ORor NRRthen each Rand Rof said ORor NRRis H.16. The method of wherein Ris NHand Ris H.17. The method of wherein Ris optionally substituted (C-C)aryl.19. The method of wherein the compound of Formula VIII is dissolved in an ether solvent and the crystallization is induced by addition of a C-Chydrocarbon.20. The method of wherein the compound of Formula VIII is dissolved in diethyl ether or methyl-t-butyl ether and crystallization is induced by the addition of hexane.21. The method of wherein the compound of Formula VIII is dissolved in diethyl ether and crystallization is induced by the addition of hexane.24. The method of wherein the compound of Formula VIII is dissolved in an ether solvent and the crystallization is induced by addition of a C-Chydrocarbon.25. The method of wherein the compound of Formula VIII is dissolved in diethyl ether or methyl-t-butyl ether and crystallization is induced by the addition of hexane.26. The method of wherein the compound of Formula VIII is dissolved in diethyl ether and crystallization is induced by the addition of hexane.29. The method of wherein Ris H and one of Ror Ris H.30. The method of wherein Ris optionally substituted (C-C)alkyl and Ris optionally substituted (C-C)aryl.31. The method of wherein Ris optionally substituted phenyl.32. ...

Подробнее
Номер записи: 58
31-10-2013 дата публикации

METHODS AND COMPOSITIONS FOR EXTRACTION AND STORAGE OF NUCLEIC ACIDS

Номер: US20130289265A1
Автор: Kvam Erik Leeming, Li Bing, Moore David Roger
Принадлежит: GENERAL ELECTRIC COMPANY

The present disclosure generally relates to solid matrices for the extraction, stabilization, and storage of nucleic acids, particularly RNA, in a dry format under ambient conditions for a prolonged period of time. Methods for extracting, collecting, and recovering nucleic acids from the solid compositions are also described. 1. A solid matrix for extraction and storage of nucleic acids from a sample , wherein a composition comprising at least one protein denaturant , at least one reducing agent , and a buffer is present in the solid matrix in a dry state.2. The solid matrix of claim 1 , wherein the sample is a biological sample.3. The solid matrix of claim 1 , wherein the composition present in the solid matrix further comprises a UV inhibitor claim 1 , a free-radical trap claim 1 , a chelator claim 1 , or any combination thereof.4. The solid matrix of claim 1 , wherein the composition present in the solid matrix further comprises an RNase inhibitor.5. The solid matrix of claim 1 , wherein the solid matrix permits prolonged storage of nucleic acids in a dry format under ambient conditions.6. The solid matrix of claim 5 , wherein the nucleic acids are RNA claim 5 , DNA claim 5 , or a combination thereof.7. The solid matrix of claim 6 , wherein the nucleic acids are RNA.8. The solid matrix of claim 1 , wherein the solid matrix is a porous matrix comprising cellulose claim 1 , cellulose acetate claim 1 , glass fiber claim 1 , or any combination thereof.9. The solid matrix of claim 8 , wherein the porous matrix is a cellulose paper.10. The solid matrix of claim 1 , wherein the protein denaturant is selected from the group consisting of guanidinium hydrochloride claim 1 , guanidinium thiocyanate (GITC) claim 1 , arginine claim 1 , sodium dodecyl sulfate (SDS) claim 1 , urea claim 1 , and any combination thereof.11. The solid matrix of claim 1 , wherein the reducing agent is selected from the group consisting of dithiothreitol (DTT) claim 1 , 2-mercaptoethanol (2-ME) ...

Подробнее
Номер записи: 59
31-10-2013 дата публикации

Spiroannulated Nucleosides and Process for the Preparation Thereof

Номер: US20130289266A1
Автор: Chepuri Venkata Ramana, Dushing Mangesh Pandurang
Принадлежит: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

We claim a simple strategy for the synthesis of a collection of C(3′)-spirodihydroisobenzo- furannulated and C(3′)-spirodihydroisobenzo-furannulated nucleosides featuring a [2+2+2]-cyclotrimerization as the key reaction. The cyclotrimerization reactions are facile with the unprotected nucleosides having a diyne unit. When both alkynes of the diyne are terminal, the regioselectivity is poor. However, when one of the terminal alkynes is additionally substituted, the cyclotrimerizations are highly diaste reoselective. Since the key bicycloannulation is the final step, this strategy provides flexibility in terms of the alkynes and is thus amenable for the synthesis of a focussed small molecule library. 3. The Spiro annulated nucleoside of general formula I as claimed in is represented by the group of the following compounds{'smallcaps': 'D', '1-[3-C,3-O-(o-Phenylenemethylene)-β--ribofuranosyl]uracil (18){'smallcaps': 'D', '1-[3-C,3-O-(o-Phenylenemethylene)-β--ribofuranosyl]thymine (19){'smallcaps': 'D', '1-[3-C3-O-(o-Phenylenemethylene)-β--ribofuranosyl]5-flurouracil (20){'smallcaps': 'D', '1-[3-C,3-O-{o-(3,4-Di-acetyloxymethyl)-phenylenemethylene}-β--ribofuranosyl]uracil (24){'smallcaps': 'D', '1-[3-C,3-O-{o-{3,4-Di-acetyloxymethyl)-phenylenemethylene}-β--ribofuranosyl]thymine (25){'smallcaps': 'D', '1-[3-C,3-O-{o-(3,4-Di-acetyloxymethyl)-phenylenemethylene}-β--ribofuranosyl]5-flurouracil (26){'smallcaps': 'D', '1- [3-C,3-O-{o-(3,4-Di-acetyloxymethyl)-phenylenemethylene}-β--ribopyranosyl]uracil (27){'smallcaps': 'D', '1-[3-C,3-O-{o-(3,4-Di-acetyloxymethyl)-phenylenemethylene}-β--ribopyranosyl]thymine (28){'smallcaps': 'D', '1- [3-C,3-O-{o-(3,4-Di-acetyloxymethyl)-phenylenemethylene}-β--ribopyranosyl]5-flurouracil (29){'sup': 'n', 'smallcaps': 'D', '1-[3-C,3-O-{o-(¾-Pentyl)-phenylenemethylene}-β--ribofuranosyl]uracil (30){'sup': 'n', 'smallcaps': 'D', '1- [3-C,3-O-{o-(¾-Pentyl)-phenylenemethylene}-β--ribofuranosyl]thymine (31){'sup': 'n', 'smallcaps': 'D', '1-[3-C,3-O-{ ...

Подробнее
Номер записи: 60
07-11-2013 дата публикации

Method for Isolation of Nucleic Acid Containing Particles and Extraction of Nucleic Acids Therefrom

Номер: US20130295574A1
Автор: Russo Leileata M., Skog Johan K.
Принадлежит: EXOSOME DIAGNOSTICS, INC.

A method for extracting nucleic acids from a biological sample by isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction, and extracting nucleic acids from the isolated particles. The centrifugation procedures are performed at a speed not exceeding about 200,000 g. The extracted nucleic acids contain both 18S and 28S rRNA. 1. A method for extracting nucleic acids from a biological sample , comprising the steps of:a. isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, wherein none of the centrifugation procedures are performed at a speed exceeding about 200,000 g;b. performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction; andc. extracting nucleic acids from the isolated particles.2. The method of claim 1 , wherein the nucleic acid-containing particles are microvesicles claim 1 , RNA-protein complexes claim 1 , DNA-protein complexes claim 1 , or a combination of any of microvesicles claim 1 , RNA-protein complexes claim 1 , and DNA-protein complexes.3. The method of claim 1 , wherein the nucleic acid-containing particles are microvesicles.4. The method of claim 1 , wherein the nucleic acid-containing particles are RNA-protein complexes.5. The method of claim 1 , wherein the nucleic acid-containing particles are DNA-protein complexes.6. The method of claim 1 , wherein all of the centrifugation procedures are performed at speeds of about 2 claim 1 ,000 g to about 200 claim 1 ,000 g.7. The method of claim 1 , wherein none of the centrifugation procedures are performed at a speed exceeding about 50 claim 1 ,000 g.8. The method of claim 1 , wherein none of the centrifugation procedures are performed at a speed exceeding about 20 claim 1 ,000 g.9. The method of claim 1 ...

Подробнее
Номер записи: 61
14-11-2013 дата публикации

CARTRIDGE FOR USE IN AN AUTOMATED SYSTEM FOR ISOLATING AN ANALYTE FROM A SAMPLE, AND METHODS OF USE

Номер: US20130302787A1
Автор: Agarwal Abhishek K., Ashkenazi Renana, Fisher Mark J., Gleason Paul J., Groves Jacqueline R., Hsu Henry H., Kelso David M., McFall Sally M., Mossberg Mark E., Parpia Zaheer, Sur Kunal, Westberg Tom
Принадлежит:

A device for extraction or isolation of an analyte, such as a nucleic acid, a protein, or a cell, from a sample, and in particular from a biological sample, is described. Methods of using the device are also described. Further processes, such as amplification of the isolated analyte, may also be carried out within the device. 1. A sample processing device , comprising:a rigid body having a first side and a second side, and defining at least:a first cavity, a second cavity, and a third cavity, wherein the first, second and third cavities are associated with first, second, and third storage compartments, respectively, each containing a water-miscible liquid reagent,a first channel, connecting the first cavity and the second cavity, anda second channel region, in fluid communication with and downstream of the second cavity, and connected to the third cavity via a third channel, at a first intersection,wherein said second channel region is associated with a storage compartment containing a water-immiscible fluid,a wall member secured to at least a portion of the first side of the rigid body, said wall member disposed over the first cavity, the second cavity, and the third cavity, thereby defining a first chamber, a second chamber, and a third chamber; andan inlet port in communication with the first chamber.2. The device of claim 1 , wherein said second channel region is in communication with said first channel and first cavity only via said second cavity.3. The device of claim 1 , wherein said storage compartment containing a water-immiscible fluid contains a volume of said fluid that is sufficient claim 1 , when dispensed to said second channel region from said storage compartment claim 1 , to produce a continuous layer of said fluid within the second channel region that includes said first intersection.4. The device of claim 1 , wherein said wall member comprises a plurality of blister regions defining said liquid reagent storage compartments.5. The device of claim 1 ...

Подробнее
Номер записи: 62
14-11-2013 дата публикации

Methods of directly extracting microrna from microvesicle in cell line, cell culture, or body fluid

Номер: US20130302856A1
Автор: Chang-Eun Yoo, Ga-hee KIM, Myoung-soon KIM
Принадлежит: SAMSUNG ELECTRONICS CO LTD

A method of extracting a nucleic acid from a microvesicle, the method comprising treating the microvesicle with a composition comprising a detergent and an aprotic solvent to extract a nucleic acid from the microvesicle.

Подробнее
Номер записи: 63
14-11-2013 дата публикации

PLANT EXTRACTION METHOD AND COMPOSITIONS

Номер: US20130303470A1
Автор: Smothers Donald L.
Принадлежит:

The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as , through use of aloe. It further provides for compositions resulting from such extractions, pharmaceutical compositions, cosmetic compositions, and methods of treating skin conditions. 1. A cardiac glycoside aloe composition , comprising a cardiac glycoside aloe extract , wherein the cardiac glycoside aloe extract is prepared by extracting a cardiac glycoside plant species with aloe to create an extraction mixture comprising a liquid material and a solid material and separating the solid material from the liquid material , wherein the liquid material comprises the cardiac glycoside aloe extract.2. The composition of claim 1 , wherein the cardiac glycoside plant species is in a family selected from the group consisting of Apocynaceae claim 1 , Brassicaceae claim 1 , Plantaginaceae claim 1 , Ruscaceae claim 1 , and Hyacinthaceae.3Nerium, Strophanthus, Apocynum, Thevetia, Catharanthus, Cheiranthus, Digitalis, ConvallariaUrginea.. The composition of claim 1 , wherein the cardiac glycoside plant species is in a genus selected from the group consisting of claim 1 , and4Nerium oleander, Thevetia nerifolia, Digitalis purpurea, Digitalis lanate, Convallaria majalis, Urginea maritima, Urginea indica, Strophanthus gratus, Apocynum cannabinumChemanthus cheiri.. The composition of claim 1 , wherein the cardiac glycoside plant species is selected from the group consisting of claim 1 , and5. The composition of claim 1 , further comprising polysaccharides.6. A pharmaceutical composition comprising the cardiac glycoside aloe composition of claim 1 , and further comprising a pharmaceutically acceptable carrier.7. The pharmaceutical composition of in pill claim 6 , sublingual or cosmetic form.8. The pharmaceutical composition of claim 6 , wherein the pharmaceutically acceptable carrier comprises a dermal agent.9. The pharmaceutical composition of claim ...

Подробнее
Номер записи: 64
14-11-2013 дата публикации

PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE AMINES

Номер: US20130303741A1
Автор: Gore Vinayak Govind, KOKANE Dattatrey, MANOJKUMAR Bindu, SONAWANE Sandeep, TANK Sinderpal
Принадлежит:

The present invention relates to an improved process for the preparation of (R)-1-aminoindan (2), rasagiline (1) and pharmaceutically acceptable salts of rasagiline. 1. A process for the preparation of enantiomerically pure (R)-2-methylamino-1-phenyl-propane comprising the formation of a diastereomeric salt of 2-methylamino-1-phenyl-propane with 2 ,3 ,4 ,6-di-O-isopropylidene-2-keto-L-gulonic acid.2. A process according to claim 1 , wherein the salt formation takes place in an organic solvent or a mixture of an organic solvent and water.3. A process according to claim 2 , wherein the organic solvent is a C-Calcohol.4. A process according to claim 3 , wherein the organic solvent is selected from the group comprising methanol claim 3 , ethanol claim 3 , n-propanol claim 3 , isopropanol claim 3 , n-butanol claim 3 , isobutanol claim 3 , tert-butanol and mixtures thereof.5. A process according to claim 4 , wherein the organic solvent is methanol or a mixture of methanol and water.6. A process according to claim 1 , wherein the diastereomeric salt formed is recrystallised.7. A process according to claim 6 , wherein the diastereomeric salt formed is recrystallised from an organic solvent or water or a mixture thereof.8. A process according to claim 7 , wherein the diastereomeric salt formed is recrystallised from a mixture of an organic solvent and water.9. A process according to claim 7 , wherein the organic solvent is a C-Calcohol.10. A process according to claim 9 , wherein the organic solvent is selected from the group comprising methanol claim 9 , ethanol claim 9 , n-propanol claim 9 , isopropanol claim 9 , n-butanol claim 9 , isobutanol claim 9 , tert-butanol and mixtures thereof.11. A process according to claim 10 , wherein the diastereomeric salt formed is recrystallised from a mixture of methanol and water.12. A process according to claim 11 , wherein the methanol to water ratio is between from about 1:0.75 to 1:1.5.13. A process according to claim 1 , wherein ...

Подробнее
Номер записи: 65
14-11-2013 дата публикации

MIXED SUPER CRITICAL FLUID HYDROLYSIS AND ALCOHOLYSIS OF CELLULOSE TO FORM GLUCOSE AND GLUCOSE DERIVATIVES

Номер: US20130303742A1
Автор: Berry William, Sutterlin William Rusty, Tegen Mark G.
Принадлежит:

The present invention relates to a process for generating glucose and glucose derivatives from the direct contacting of cellulose, hemicelluloses and/or polysaccharides with a mixed super critical fluid system of alcohol and water whereby the partial pressure of the system provides for both alcoholysis and hydrolysis of the material to generate primarily glucose, and glucose derivatives. 1. A method for making a hexose , a pentose , an alkyl glucoside , or an alkyl pentoside , the method comprising:(a) (i) combining a feedstock with an alcohol and water,wherein the feedstock comprises a cellulosic material, a protein, or both a cellulosic material and a protein; or(ii) combining a feedstock with an alcohol and water,wherein the feedstock comprises a cellulosic material, a hemicellulose-comprising material, or both a cellulosic material and a hemicellulose-comprising material; and(b) reacting the feedstock and the alcohol and water at a temperature in the range of between about 140° C. to 350° C., and at a pressure in a range of between about 500 psig to 3200 psig to cleave the cellulosic material to generate a product comprising a hexose, a pentose, an alkyl glucoside, or an alkyl pentoside.2. The method of claim 1 , wherein the feedstock comprises at least about 10 wt % cellulosic material based on the dry weight of the feedstock.3. The method of claim 1 , wherein the feedstock comprises at least about 10 wt % proteins based on the dry weight of the feedstock.4. The method of claim 1 , wherein the water content of the combination of (a)(ii) before the reaction of (b) is from about 30 wt % to about 300 wt % of the dry weight of the feedstock.5. The method according to claim 1 , wherein said feedstock comprises a rice husk claim 1 , a rice bran claim 1 , a corn stover claim 1 , a corn cob claim 1 , a sugar cane bagasse claim 1 , a palm fiber claim 1 , a palm kernel cake claim 1 , a wood pulp claim 1 , a pine tree material claim 1 , a fir tree material claim 1 , a ...

Подробнее
Номер записи: 66
14-11-2013 дата публикации

BUFFER FOR ONE-STEP DNA EXTRACTION

Номер: US20130303746A1
Автор: Miller Ingrid, Ruegg Bryony
Принадлежит: Bio-Rad Laboratories, Inc.

DNA is extracted from epithelial cells and other cells without cell walls, by use of a DNA extraction buffer that contains a C-Calcohol, a cell lysis detergent, and a buffering agent maintained at a slightly basic pH. The cells are immersed in the buffer and gently agitated at ambient temperature, and DNA extraction and precipitation occur in thirty minutes or less, and often in five minutes or less. 1. A process for extracting DNA from cells without cell walls , said process comprising:{'sub': 1', '4, '(a) immersing said cells in an aqueous solution comprising a C-Calcohol at from about 50% to about 85% by weight, a cell lysis detergent at from about 0.05% to about 0.5% by weight, and a buffering agent maintaining a pH of from about 7.5 to about 9.0, and substantially no protease, substantially no reducing agent, and substantially no non-detergent, inorganic salt, at a temperature of from about 15° C. to about 35° C. for from about five seconds to about thirty minutes, to cause DNA to be liberated from said cells and to precipitate; and'}(b) recovering said DNA so precipitated from said aqueous solution.2. The process of wherein said C-Calcohol is a member selected from the group consisting of methanol claim 1 , ethanol claim 1 , and isopropanol.3. The process of wherein said C-Calcohol is isopropanol or a mixture of isopropanol and ethanol.4. The process of wherein said cell lysis detergent is a denaturing detergent.5. The process of wherein said cell lysis detergent is a member selected from the group consisting of anionic and zwitterionic detergents.6. The process of wherein said cell lysis detergent is an anionic detergent.7. The process of wherein said cell lysis detergent is a member selected from the group consisting of sodium dodecyl sulfate claim 1 , sodium octadecyl sulfate claim 1 , and sodium decyl sulfate.8. The process of wherein said cell lysis detergent is sodium dodecyl sulfate.9. The process of wherein said C-Calcohol is a member selected from the ...

Подробнее
Номер записи: 67
21-11-2013 дата публикации

FLUIDIC DEVICES AND SYSTEMS FOR SAMPLE PREPARATION OR AUTONOMOUS ANALYSIS

Номер: US20130309679A1
Автор: Begolo Stefano, Homewood Philip James, Hsu Yu-Hsiang, Ismagilov Rustem F., KARYMOV Mikhail, Li Liang, McCalla Stephanie, Selck David, Shen Feng
Принадлежит:

The present invention relates to fluidic devices for preparing, processing, storing, preserving, and/or analyzing samples. In particular, the devices and related systems and methods allow for preparing and/or analyzing samples (e.g., biospecimen samples) by using one or more of capture regions and/or automated analysis. 1. A device comprising:(i) a first layer comprising a plurality of first chambers;(ii) a second layer comprising one or more second chambers; and(iii) an intermediate layer disposed between said first and second layers, wherein said intermediate layer comprises one or more capture regions,wherein at least one of said plurality of first chambers, at least one of said one or more second chambers, and at least one of said one or more capture regions are able to be connected by relative movement.2. The device of claim 1 , wherein said one or more capture regions comprise a filter claim 1 , a matrix claim 1 , a polymer claim 1 , a charge switch material claim 1 , or a membrane.3. The device of claim 1 , wherein said one or more capture regions are configured to connect two or more of said plurality of first chambers and at least one of said one or more second chambers.4. The device of claim 1 , wherein said intermediate layer comprises a continuous membrane.5. The device of claim 1 , wherein said first layer claim 1 , said second layer claim 1 , or said intermediate layer is planar or non-planar.6. The device of claim 1 , wherein said first layer claim 1 , said second layer claim 1 , or said intermediate layer claim 1 , or a portion thereof claim 1 , is differentially wetted.7. The device of claim 1 , further comprising a deformable layer between said first layer and said intermediate layer and/or between said second layer and said intermediate layer.8. The device of claim 7 , further comprising a coating on one or more of said first layer claim 7 , said intermediate layer claim 7 , said second layer claim 7 , or said deformable layer.9. The device of ...

Подробнее
Номер записи: 68
28-11-2013 дата публикации

METHOD FOR THE PURIFICATION OF A GLYCAN AND/OR A GLYCOCONJUGATE BY CHROMATOGRAPHY USING A STATIONARY PHASE COMPRISING COTTON

Номер: US20130316463A1
Автор: Hemayatkar Mahdi, Selman Maurice Henricus Johannes, Wuhrer Manfred
Принадлежит:

A method of purifying a glycan and/or a glycoconjugate comprising the steps of: (a) providing a stationary phase that comprises cotton; (b) applying a glycan and/or glycoconjugate-containing sample to the stationary phase; (c) washing the stationary phase with a first solvent; and (d) eluting the glycan and/or glycoconjugate from the stationary phase with a second solvent. A kit for purifying a glycan and/or glycoconjugate, the kit comprising: a stationary phase comprising cotton; and instructions for purifying a glycan and/or glycoconjugate according to the disclosed method. 1. A method of purifying a glycan and/or a glycoconjugate , the method comprising:applying a glycan and/or glycoconjugate-containing sample to the a stationary phase, the stationary phase comprising cotton;washing the stationary phase with a first solvent; andeluting the glycan and/or glycoconjugate from the stationary phase with a second solvent.2. The method of claim 1 , wherein the glycan and/or glycoconjugate-containing sample comprises an organic solvent claim 1 , wherein the organic solvent comprises at least one of acetonitrile claim 1 , methanol claim 1 , ethanol claim 1 , propanol claim 1 , isopropanol claim 1 , butanol claim 1 , or tetrahydrofuran.3. The method of claim 1 , wherein the first solvent is a solvent mixture comprising water claim 1 , an organic solvent and an acid claim 1 , wherein the organic solvent comprises at least one of acetonitrile claim 1 , methanol claim 1 , ethanol claim 1 , propanol claim 1 , isopropanol claim 1 , butanol claim 1 , or tetrahydrofuran claim 1 , and the acid comprises at least one of trifluoroacetic acid claim 1 , formic acid claim 1 , acetic acid claim 1 , pentafluoropropionic acid claim 1 , or heptafluorobutyric acid.4. The method of claim 1 , wherein the second solvent comprises a polar solvent wherein the polar solvent comprises at least one of water claim 1 , dimethylsulfoxide claim 1 , or dimethylformamide.5. The method of claim 1 , ...

Подробнее
Номер записи: 69
05-12-2013 дата публикации

Systems and Methods for Enhanced Nucleic acid Seperation

Номер: US20130323742A1
Автор: Marziali Andrea, Pel Joel, Shibahara Gosuke, Thompson Jason Donald
Принадлежит: The University of British Columbia

Methods and apparatus for separating, concentrating and/or detecting molecules based on differences in binding affinity to a probe are provided. The molecules may be differentially modified. The molecules may be differentially methylated nucleic acids. The methods can be used in fields such as epigenetics or oncology to selectively concentrate or detect the presence of specific biomolecules or differentially modified biomolecules, to provide diagnostics for disorders such as fetal genetic disorders, to detect biomarkers in cancer, organ failure, disease states, infection or the like. 165.-. (canceled)66. A method of separating differentially methylated nucleic acid molecules , comprising:providing first and second nucleic acid molecules, the first and second nucleic acids molecules being at least 95% identical in sequence but being differentially methylated,contacting a matrix comprising an oligonucleotide probe with the first and second nucleic acids; andapplying a time-varying electric field to the matrix while synchronously varying the mobility of the first and second nucleic acids, thereby separating the first and second nucleic acid molecules.67. The method of claim 66 , further comprising collecting the first nucleic acid molecule from the matrix.68. The method of claim 66 , further comprising collecting the second nucleic acid molecule from the matrix.69. The method of claim 66 , wherein the time-varying electric field varies the mobility of the first and second nucleic acids.70. The method of claim 69 , wherein the time-varying electric field varies the mobility by causing Joule heating within the matrix.71. The method of claim 66 , wherein the difference between the binding energy of the first nucleic acid molecule to the oligonucleotide probe and the binding energy of the second nucleic acid molecule to the oligonucleotide probe is less than about 4 kcal/mol.72. The method of claim 66 , wherein the difference between the melting temperature of the first ...

Подробнее
Номер записи: 70
05-12-2013 дата публикации

FUNGAL NUCLEIC ACID EXTRACTION

Номер: US20130323815A1
Автор: Cummins Lendell, Gundling Gerard, Ivy Cristina A., Laffler Thomas
Принадлежит: IBIS BIOSCIENCES, INC.

The invention provides methods for extraction of fungal (e.g., yeast spp., filamentous fungal spp.) nucleic acid (e.g., DNA, RNA) from a sample (e.g., be human or veterinary clinical or research samples, agricultural samples, agricultural commodity samples, food products, or environmental samples). In some embodiments, the present invention provides enhanced nucleic acid extraction from samples comprising fungal cell(s) wherein enzymatic (e.g., lysostaphin treatment, lyticase treatment) sample treatment is performed in combination with mechanical (e.g., bead beating) sample treatment. 1. A method of extracting fungal nucleic acid from a sample , comprising:a) subjecting said sample to enzymatic treatment;b) subjecting said sample to mechanical treatment; andc) extracting said nucleic acid from said sample.2. The method of claim 1 , wherein said enzymatic treatment is selected from the group consisting of lysostaphin treatment and lyticase treatment.3. The method of claim 1 , wherein said enzymatic treatment comprises treatment with lysostaphin and lyticase.4. The method of wherein said mechanical treatment is selected from the group consisting of bead beating claim 1 , grinding claim 1 , sonication claim 1 , extrusion claim 1 , freezing claim 1 , freeze-thawing claim 1 , exposure to pressure exceeding 1 atm claim 1 , exposure to pressure below 1 atm claim 1 , exposure to temperature above 37 degrees C. claim 1 , exposure to temperature below 10 degrees C. claim 1 , treatment with a hammer mill claim 1 , treatment with a knife mill claim 1 , treatment with a ball mill claim 1 , treatment with a homogenizer claim 1 , treatment with a chipping machine claim 1 , treatment with a grinding machine claim 1 , treatment with a French press claim 1 , treatment with an extrusion device claim 1 , and irradiation.5. The method of claim 1 , wherein said mechanical treatment comprises bead beating.6. The method of claim 1 , further comprising treatment of said sample with protease ...

Подробнее
Номер записи: 71
12-12-2013 дата публикации

CATALYTIC GLYCOSYLATION WITH DESIGNER THIOGLYCOSIDE AND NOVEL PROTECTING GROUPS FOR SAME AND FOR SYNTHESIS OF OLIGOSACCHARIDES

Номер: US20130331556A1
Автор: Liu Xinyu
Принадлежит:

A catalytic glycosylation method comprising: installing thioether to an anomeric carbon of a carbohydrate; and catalytically activating the thioether with a non-oxophilic Lewis acid. The thioether may comprise an anomerically stable thioether leaving group. The catalytic glycosylation method may further comprise: utilizing an acid-sensitive ester protecting group as permanent protecting group or using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process. A protecting group to mask hydroxyl functionalities in the production of oligosaccharides, natural products or any molecule having a hydroxyl group comprising an acid-labile ester protecting group. 1. A catalytic glycosylation method comprising:installing thioether to an anomeric carbon of a carbohydrate; andcatalytically activating the thioether with a non-oxophilic Lewis acid.2. The catalytic glycosylation method of wherein the thioether comprises an anomerically stable thioether leaving group.3. The catalytic glycosylation method of further comprising: utilizing an acid-sensitive ester protecting group as permanent protecting group.4. The catalytic glycosylation method of further comprising: using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process.5. The catalytic glycosylation method of further comprising: utilizing an application of a 100%-PEG-based polymer as insoluble support for solid-phase oligosaccharide synthesis.6. The catalytic glycosylation method of further comprising: utilizing a designer thioglycoside that retains basic properties of a parental thioglycoside claim 1 , including the ease of preparation and toleration of backbone protecting group manipulation.7. The catalytic glycosylation method of further comprising: applying an activator permitting an application of highly acid-sensitive protecting groups;applying a 100%-PEG-based polymer as ...

Подробнее
Номер записи: 72
12-12-2013 дата публикации

METHODS AND DEVICES FOR PRODUCING BIOMOLECULES

Номер: US20130331560A1
Автор: ASCHER Christine, NECINA Roman, URTHALER Jochen, WOEHRER Helga
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

A scalable process and device for producing a biomolecule, in particular pharmaceutical grade plasmid DNA. The process includes the steps of alkaline lysis and a neutralization. For separating the lysate and the precipitate, the mixture is allowed to gently flow downward through a clarification reactor that is partially filled, in its lower part, with retention material like glass beads, whereby the precipitate is retained on top of and within the retention. In a preferred embodiment of the lysis step, cell suspension and alkaline lysis solution flow through a lysis reactor that is filled with particulate material like glass beads. The process can be run continuously and fully automated. 139-. (canceled)40. A method of purifying a polynucleotide of interest from host cells comprising the polynucleotide of interest using a device , wherein the device comprises a lysis reactor , a neutralization reactor and a clarification reactor fluidly connected to one another , the method comprising:(a) providing a cell suspension of the host cells that have been cultivated to produce the polynucleotide of interest, wherein the cell suspension is a fermentation broth within which the host cells were cultivated or a re-suspension of the cultivated host cells that were harvested from the fermentation broth;(b) introducing a flow of the cell suspension and a flow of a lysis solution into the lysis reactor, the lysis reactor containing filling elements made of glass, plastic, stainless steel or fibrous material, such that the flow of the cell suspension and the flow of the lysis solution through the lysis reactor filling elements provides homogenous mixing of the flows in the absence of shear forces and whereby the cultivated host cells of the flowed suspension are substantially disintegrated by alkaline lysis alone to produce a lysed solution;(c) neutralizing the cell solution via the neutralization reactor, wherein the lysed cell solution is mixed with a neutralization solution to ...

Подробнее
Номер записи: 73
19-12-2013 дата публикации

METHODS FOR PURIFYING MONOSACCHARIDE MIXTURES CONTAINING IONIC IMPURITIES

Номер: US20130338086A1
Автор: Delaney Edward, Oroskar Anil
Принадлежит: Aptalis Pharma Canada Inc.

Disclosed herein are methods for separating ionic impurities from monosaccharide processing streams using simulated moving bed chromatography. 1. A method of separating an ionic impurity from a monosaccharide-containing process stream , comprising:a. contacting an ion exclusion resin within a simulated moving bed chromatography unit with the monosaccharide-containing process stream; andb. eluting the ion exclusion resin with water to produce an extract stream that comprises monosaccharides and a raffinate stream that comprises the ionic impurity,thereby separating the ionic impurity from the monosaccharide-containing process stream.2. A method of separating an ionic impurity from a saccharide-containing process stream , comprising:a. providing the saccharide containing process stream, wherein the process stream further comprises an inorganic dianion;b. contacting an ion exclusion resin within a simulated moving bed chromatography unit with the saccharide-containing process stream; andc. eluting the ion exclusion resin with an aqueous eluent to produce an extract stream that comprises saccharides and a raffinate stream comprises the ionic impurity,thereby separating the ionic impurity from the saccharide-containing process stream.3. The method of claim 1 , wherein the method is continuous.4. The method of claim 1 , further comprising isolating the extract steam that comprises the monosaccharides or saccharides.5. The method of claim 1 , further comprising isolating the raffinate stream that comprises water soluble inorganic and organic salts of sodium and ammonium.6. The method of claim 5 , wherein the water soluble inorganic salts of sodium and ammonium comprise sodium sulfate and ammonium sulfate.7. The method of claim 5 , wherein the water soluble organic salts of sodium and ammonium comprise sodium aldonate and ammonium aldonates.8. The method of claim 1 , wherein the monosaccharide or saccharide containing process stream comprises an L-monosaccharide.9. The ...

Подробнее
Номер записи: 74
19-12-2013 дата публикации

Novel Compound Isolated from Allium tuberosum and Use Thereof as Antiviral Agent

Номер: US20130338090A1
Автор: Cho Sang Buem, Kim Soo Ki, Lee Jun Hyeong, Moon Hyung In, Paik Hyun Dong, Seo Sang Heui
Принадлежит:

The present invention relates to a novel compound isolated from and the use thereof as an antiviral agent. The compound isolated from shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent. 2Allium tuberosumAllium tuberosum. A method of obtaining the compound of from claim 1 , the method comprising the steps of: treating with an organic solvent to obtain an organic solvent extract;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'suspending the organic solvent extract in water; treating the suspension with chloroform to obtain an chloroform fraction; and obtaining the compound of from the chloroform fraction.'}3. The method of claim 2 , wherein the organic solvent is a Cto Calcohol.4. The method of claim 3 , wherein the alcohol is methanol.5. A pharmaceutical composition for preventing or treating viral disease claim 1 , comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.6. The pharmaceutical composition of claim 5 , wherein the viral disease is avian influenza viral disease.7. The pharmaceutical composition of claim 6 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.8Allium tuberosum.. A feed composition for preventing or treating viral disease claim 1 , comprising the compound of or a methanol fraction of9. The feed composition of claim 8 , wherein the viral disease is avian influenza virus.10. The feed composition of claim 9 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.11. A method for preventing or treating viral disease claim 1 , comprising a step of administering an effective amount of the compound of or a pharmaceutically acceptable salt thereof to a subject in need of prevention or treatment of viral disease.12. The method of claim 11 , wherein the viral disease is avian influenza viral disease.13. The method of claim 12 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.14Allium tuberosum. ...

Подробнее
Номер записи: 75
19-12-2013 дата публикации

Isolation of nucleic acids

Номер: US20130338245A1
Автор: Matthew Baker
Принадлежит: Life Technologies Corp

A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.

Подробнее
Номер записи: 76
19-12-2013 дата публикации

METHOD FOR ISOLATING NUCLEIC ACIDS

Номер: US20130338350A1
Автор: Elias Dwayne A., Hurt, JR. Richard Ashley
Принадлежит:

The current disclosure provides methods and kits for isolating nucleic acid from an environmental sample. The current methods and compositions further provide methods for isolating nucleic acids by reducing adsorption of nucleic acids by charged ions and particles within an environmental sample. The methods of the current disclosure provide methods for isolating nucleic acids by releasing adsorbed nucleic acids from charged particles during the nucleic acid isolation process. The current disclosure facilitates the isolation of nucleic acids of sufficient quality and quantity to enable one of ordinary skill in the art to utilize or analyze the isolated nucleic acids for a wide variety of applications including, sequencing or species population analysis. 1. A method for isolating nucleic acids from an environmental sample , comprising:(i) obtaining an environmental sample comprising cells;(ii) subjecting the sample to a lysis process comprising mixing the sample with a lysis solution in the presence of liquid nitrogen, thereby obtaining a lysed material;(iii) subjecting the lysed material to an extraction process by mixing the lysed material with an extraction solution, and subjecting the resulting mixture to centrifugation;(iv) collecting the supernatant after the centrifugation;(v) washing the pellet obtained after the centrifugation of step (iii) with a wash solution comprising sodium phosphate at a concentration of at least 300 mM, and collecting the supernatant from the wash; and(vi) combining the collected supernatants from step (iv) and step (v), and isolating nucleic acids from the collected supernatants.2. The method of claim 1 , wherein the environmental sample is selected from the group consisting of soil claim 1 , clay claim 1 , sediment claim 1 , water or liquid claim 1 , and a combination thereof.3. The method of claim 1 , wherein said lysis solution comprises sodium phosphate at a concentration of at least 300 mM.4. The method of claim 1 , wherein said ...

Подробнее
Номер записи: 77
19-12-2013 дата публикации

METHODS AND COMPOSITIONS FOR EXTRACTION AND STORAGE OF NUCLEIC ACIDS

Номер: US20130338351A1
Автор: Bales Brian Christopher, Kvam Erik Leeming, Li Bing
Принадлежит: GENERAL ELECTRIC COMPANY

A solid matrix for the extraction, stabilization, and storage of nucleic acids is provided. At least one protein denaturant, and at least one acid or acid-titrated buffer reagent are impregnated in a dry state therein the matrix; and the matrix is configured to provide an acidic pH on hydration. The matrix is configured to extract nucleic acids from a sample and stabilize the extracted nucleic acids, particularly RNA, in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the nucleic acids stored in the dry solid matrix are also described. 2. The matrix of is a solid phase extraction matrix.3. The matrix of claim 1 , wherein the extracted and preserved nucleic acids comprise ribonucleic acids (RNA) claim 1 , deoxy ribonucleic acids (DNA) or a combination thereof.4. The matrix of claim 1 , wherein the extracted and preserved nucleic acids comprise RNA.5. The matrix of claim 4 , wherein the extracted and preserved RNA has an RNA integrity number (RIN) of at least 4.6. The matrix of claim 1 , wherein the acid comprises acetic acid claim 1 , citric acid claim 1 , tartaric acid claim 1 , phosphoric acid claim 1 , hydrochloric acid claim 1 , Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-HCl) claim 1 , oxidized Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-O—HCl) claim 1 , sulfuric acid claim 1 , nitric acid claim 1 , vanillic acid claim 1 , 3-(N-morpholino)propanesulfonic acid or combinations thereof.7. The matrix of claim 1 , wherein the acid-titrated buffer reagent generates a pH in a range from 2 to 7.8. The matrix of claim 1 , wherein the acid-titrated buffer reagent generates a pH in a range from 3 to 6.9. The matrix of further comprising a UV protectant claim 1 , a free-radical scavenger claim 1 , a chelator or combinations thereof.10. The matrix of claim 9 , wherein the UV protectant or free-radical scavenger is selected from the group consisting of hydroquinone monomethyl ether (MEHQ) claim ...

Подробнее
Номер записи: 78
26-12-2013 дата публикации

PURIFIED CARDIOGENIN ISOMER AND RELATED METHODS

Номер: US20130345159A1
Автор: Elliott Gary, Freund Ernst, Kyas Andreas, Lill Joerg, Menia Dario, Paterniti James, Rogall Lars, Schlörke Oliver
Принадлежит: HUYA BIOSCIENCE INTERNATIONAL LLC

A cardiogenin major isomer is obtained from a methanol extract of and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w). 2. The compound according to claim 1 , wherein the compound has at least 98.97% (a/a) HPLC purity at 210 nm.3. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable carrier.4Geum japonicumGeum japonicum. An improved method of extracting the compound according to from comprising the steps of (A) precipitating and filtering an methanolic/water solution of to remove of unwanted solids claim 1 , (B) phase separative extracting the methanol/water solution with dichloromethane and TBME claim 1 , and (C) extracting with n-butanol.5. The method according to further comprising subjecting a composition comprising the compound according to to low pressure Diaion HP-20 adsorption chromatography using an optimal mass ration of resin to material load (15:1) and a step gradient of methanol/water claim 1 , followed by low pressure silica gel chromatography using an optimal mass ration of resin to material load (20:1) and a step gradient of dichloromethane/methanol.6. The method according to further comprising subjecting a composition comprising the compound according to to high pressure reverse phase chromatography using aqueous buffer and methanol mobile phases in a gradient program.7. The method according to claim 6 , wherein the high pressure reverse phase chromatography comprises using a Luna® C18 (2) column.8Geum japonicum. A method of isolating the compound according to claim 1 , comprising the steps of (A) obtaining an extract from the methanol extract of and (B) subjecting the extract to ...

Подробнее
Номер записи: 79
02-01-2014 дата публикации

METHOD AND APPARATUS FOR TREATMENT OF BIOMASS SUBSTRATES

Номер: US20140004563A1
Автор: DADI Anantharam, PARIPATI Praveen
Принадлежит: SUGANIT SYSTEMS, INC.

A system and method for the treatment of biomass comprising mixing a biomass with an ionic liquid (IL) to swell the biomass and electromagnetic (EM) heating, preferably radiofrequency (RF) heating, said biomass. Additionally, a method of acidolysis of biomass comprising mixing biomass in an ionic liquid (IL) to swell the biomass; adding an acid, to lower the pH of the biomass below pH 7; applying radio frequency (RF) heating to the biomass to heat to a target temperature range; applying ultrasonic heating, electromagnetic (EM) heating, convective heating, conductive heating, or combinations thereof, to the biomass to maintain the biomass at a target temperature range; washing the treated biomass; and recovering sugars and released lignin. 1. A method for the treatment of biomass comprising mixing a biomass with an ionic liquid (IL) to swell said biomass and electromagnetic (EM) heating , said swelled biomass.2. The method of claim 1 , wherein said biomass is agricultural residues claim 1 , optionally corn stover claim 1 , wheat straw claim 1 , bagasse claim 1 , rice hulls claim 1 , or rice straw; wood and forest residues claim 1 , optionally pine claim 1 , poplar claim 1 , douglas fir claim 1 , oak claim 1 , saw dust claim 1 , paper/pulp waste claim 1 , or wood fiber; algae; kudzu; coal; cellulose claim 1 , lignin claim 1 , herbaceous energy crops claim 1 , optionally switchgrass claim 1 , reed canary grass claim 1 , or miscanthus; lingocellulosic biomass claim 1 , optionally comprising lignin claim 1 , cellulose claim 1 , and hemicellulose; plant biomass; or mixtures thereof.3. The method of claim 1 , wherein heating comprises at least two phases claim 1 , a first phase comprising application of electromagnetic (EM) heating claim 1 , optionally a variable frequency in the electromagnetic spectrum claim 1 , variable frequency heating claim 1 , radiofrequency (RF) heating claim 1 , or a combination thereof claim 1 , and a second phase comprising application of ...

Подробнее
Номер записи: 80
02-01-2014 дата публикации

Method of extracting kaempferol-based antioxidants from solenostemma arghel

Номер: US20140005373A1
Автор: Amani Shafeek Awaad, Reham Moustafa El-Meligy
Принадлежит: KING SAUD UNIVERSITY

The method of extracting kaempferol-based antioxidants from Solenostemma arghel provides a method of producing medicinal antioxidants for usage as anti-inflammatory and analgesic treatments. The kaempferol-based antioxidants are primarily kaempferol-3,4′-diglucoside and kaempferol 3-rutinoside. The method includes the following steps: collecting aerial parts of Solenostemma arghel; drying the aerial parts; powdering the aerial parts; extracting the powdered aerial parts in ethanol and filtering to produce a filtrate; concentrating the filtrate to form a concentrated residue; dissolving the concentrated residue in water; and extracting the kaempferol-based antioxidant from the dissolved residue in ethyl acetate.

Подробнее
Номер записи: 81
09-01-2014 дата публикации

Synthetic Lipid A Derivative

Номер: US20140011987A1
Автор: BOONS Geert-Jan
Принадлежит: University of Georgia Research Foundation, Inc.

The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative. 2. The compound of wherein Ris tert-butyldimethylsilyl (TBS) or dimethylthexylsilyl (TDS).3. The compound of wherein Ris azido.4. The compound of wherein Ris an amino protecting group comprising 9-fluorenylmethoxycarbamate (Fmoc).5. The compound of wherein Ris a hydroxyl protecting group comprising allyloxycarbonate (Alloc).6. The compound of wherein Ris an amino protecting group comprising 9-fluorenylmethoxycarbamate (Fmoc).7. The compound of wherein Ris a hydroxyl protecting group comprising allyloxycarbonate (Alloc) or levulinate (Lev).8. The compound of wherein Rand Rtogether form a ring comprising an acetal.10. The method of wherein selectively acylating the functionalized disaccharide comprises selectively acylating the functionalized disaccharide at two claim 9 , three or four of positions C-2 claim 9 , C-3 claim 9 , C-2′ and C-3′ of the functionalized disaccharide.11. The method of further comprising phosphorylating the functionalized disaccharide at either or both of the C-1 or C-4′ positions of the functionalized disaccharide.12. The method of further comprising contacting the functionalized disaccharide with a 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) donor to yield a KDO glycoside at the C-6′ position of the functionalized disaccharide.13. The method of wherein Ris tert-butyldimethylsilyl (TBS) or dimethylthexylsilyl (TDS).14. The method of wherein Ris azido.15. The method of wherein Ris an amino protecting group comprising 9-fluorenylmethoxycarbamate (Fmoc).16. The method of wherein Ris a hydroxyl protecting group comprising allyloxycarbonate (Alloc). This application is a continuation application of U.S. application Ser. No. 12/676,253, filed Apr. 19, 2010, which is national stage application of International Application No. PCT/US2008/010394, filed ...

Подробнее
Номер записи: 82
23-01-2014 дата публикации

SYSTEMS AND METHODS FOR IMPROVING FERMENTATION

Номер: US20140024826A1
Автор: Bly Steven T., Narendranath Neelakantam V.
Принадлежит:

Systems and methods for increasing fermentation efficiency of a lignocellulosic hydrolysate are disclosed. The system comprises a filter configurable to remove matter having a particle size of larger than about 25 to 100 microns from the liquid component, and at least one nanofilter configurable to remove acids from the liquid component. An apparatus is used to adjust the pH of the nanofiltered liquid component using a calcium hydroxide composition to a pH of about 5.5 to 6.0. The calcium hydroxide composition includes calcium hydroxide alone or in combination with either ammonium hydroxide and/or potassium hydroxide. The biomass comprises lignocellulosic material including at least one of corncob, corn plant husk, corn plant leaves, and corn plant stalks. 1. A system for treating a liquid component separated from biomass to yield a treated liquid component comprising sugars available to be fermented into a fermentation product comprising:a filter configured to remove matter having a particle size of larger than about 25 microns from the liquid component;at least one nanofilter configured to remove acids and concentrate xylose in the filtered liquid component; andan apparatus configured to adjust a pH of the nanofiltered liquid component using a calcium hydroxide composition.2. The system of claim 1 , wherein the biomass comprises lignocellulosic material claim 1 , wherein the lignocellulosic material comprises at least one of corn cob claim 1 , corn plant husk claim 1 , corn plant leaves claim 1 , and corn plant stalks.3. The system of claim 1 , wherein the filter has a pore size of 0.1 to 20 micrometers.4. The system of claim 1 , wherein the at least one nanofilter includes a first nanofiltration stage and a second nanofiltration stage.5. The system of claim 4 , wherein the second nanofiltration stage comprises a membrane with pores that allow water molecules and acid ions to pass as permeate and retain sugar molecules as retentate claim 4 , wherein the ...

Подробнее
Номер записи: 83
30-01-2014 дата публикации

COMPOUNDS

Номер: US20140031534A1
Автор: BORGOS Sven Even Finn, BRAUTASET Trygve, ELLINGSEN Trond Erling, OLSUFYEVA Evgenia Nikolaevna, PREOBRAZHENSKAYA Maria Nikolaevna, SLETTA Havard, ZOTCHEV Sergey Borisovich
Принадлежит: BIOSERGEN AS

The present invention provides a compound which is a nystatin derivative having an additional double bond present between C28 and C29 and which is further modified relative to nystatin at one or more of positions C5, C7, C9, C10, C11, C16 or at the amino group of mycosamine. 132.-. (canceled)34. A compound as claimed in which is modified at position C5 relative to nystatin.35. A compound as claimed in which is modified at C9 relative to nystatin.36. A compound as claimed in which is modified at C10 relative to nystatin.37. A compound as claimed in which is modified at the amino group of mycosamine.38. A compound as claimed in wherein Rrepresents a hydrogen atom claim 33 , a hydroxyl group or an alkoxy group (e.g. a group —OC) and Ris a hydrogen atom or wherein Rand Rtogether form a carbonyl group.39. A compound as claimed in claims 33 , wherein Rrepresents a hydrogen atom claims 33 , a hydroxyl group or an alkoxy group (e.g. a group —OC) and Ris a hydrogen atom or wherein Rand Rtogether form a carbonyl group.40. A compound as claimed in claim 33 , wherein Rrepresents a hydrogen atom claim 33 , a hydroxyl group or an alkoxy group (e.g. a group —OC) and Ris a hydrogen atom41. A compound as claimed in claim 33 , wherein Rrepresents a hydrogen atom claim 33 , an alkylamino group claim 33 , a sugar or an acyl group and Ris identical to Ror is a hydrogen atom claim 33 , e.g. Ris a hydrogen atom.43. A compound as claimed in wherein Ris methyl claim 42 , CONH(CH)N(CH)or CONH(CH)OH where n is 2 or 3.44. A compound as claimed in claim 33 , wherein Ris an alkylamino group of the formula —(CH)NHor —(CH)N(Calkyl)wherein x is 2 to 6 or is a monosaccharide selected from glucose claim 33 , galactose claim 33 , glucopyranose claim 33 , mannopyranose claim 33 , galactopyranose claim 33 , fructopyranose and tagotopyranose or is an oligosaccharide selected from lactose claim 33 , melibiose claim 33 , sucrose claim 33 , maltose and cellobiose.45. A compound as claimed in claim 33 , ...

Подробнее
Номер записи: 84
06-02-2014 дата публикации

Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides

Номер: US20140039175A1
Автор: Srivastava Suresh C., Yasko Amy
Принадлежит:

The present invention is directed towards the synthesis of high purity deuterated sugars, deuterated phosphoramidites, deuterated nucleobases, deuterated nucleosides, deuterated oligonucleotides, and deuterated RNA's of defined sequences which can exhibit biochemically useful and biologically valuable properties, thus having potential for therapeutic uses. 2. The modified ribo-oligonucleotide according to wherein W is oxygen and Y is oxygen.3. The modified ribo-oligonucleotide according to wherein W is sulfur and Y is oxygen.4. The modified ribo-oligonucleotide according to wherein at least one deuterium is replaced by a hydrogen.5. The modified ribo-oligonucleotide according to wherein said B is a naturally occurring nucleobase claim 1 , a modified nucleobase claim 1 , or combinations thereof.6. The modified ribo-oligonucleotide according to wherein B includes a purine claim 1 , a pyrimidine claim 1 , or combinations thereof.7. The modified ribo-oligonucleotide according to wherein B is partially or fully deuterated.8. The modified oligonucleotide according to wherein B is deuterioadenine claim 7 , deuteriocytidine claim 7 , deuterioguanine claim 7 , deuteriouracil claim 7 , or combinations thereof.9. The modified ribo-oligonucleotide according to wherein said nucleotide has a variant internucleotide linkage.10. The modified ribo-oligonucleotide according to wherein said ribose sugars are fully deuterated.11. The modified ribo-oligonucleotide according to wherein said ribose sugars are partially deuterated.12. The modified ribo-oligonucleotide according to having a mixture of fully deuterated ribose sugars and partially deuterated ribose sugars.13. The modified ribo-oligonucleotide according to wherein said B′ claim 9 , B″ claim 9 , and B′″ is a naturally occurring nucleobase claim 9 , a modified nucleobase claim 9 , or combinations thereof.14. The modified ribo-oligonucleotide according to wherein B′ claim 12 , B″ claim 12 , and B′″ claim 12 , includes a purine ...

Подробнее
Номер записи: 85
06-02-2014 дата публикации

Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides

Номер: US20140039178A1
Автор: Srivastava Suresh C., Yasko Amy
Принадлежит:

The present invention is directed towards the synthesis of high purity deuterated sugars, deuterated phosphoramidites, deuterated nucleobases, deuterated nucleosides, deuterated oligonucleotides, and deuterated RNA's of defined sequences which can exhibit biochemically useful and biologically valuable properties, thus having potential for therapeutic uses. 2. The modified phosphoramidite according to wherein said R1 is dimethoxytrityl protecting group claim 1 , R2 is t-butyldimethylsilyl protecting group claim 1 , R3 is diiopropylamino protecting group claim 1 , and R4 is a 3′-O-cyanoethyl protecting group.3. The modified phosphoramidite according to wherein said B contains a blocking group.4. The modified phosphoramidite according to wherein said nucleobase is a natural base.5. The modified phosphoramidite according to wherein said natural base is adenine.6. The modified phosphoramidite according to wherein said natural base is guanine.7. The modified phosphoramidite according to wherein said natural base is cytosine.8. The modified phosphoramidite according to wherein said natural base is uracil.9. The modified phosphoramidite according to wherein said nucleobase is a modified nucleobase.10. The modified phosphoramidite according to wherein said modified base is deuteratedadenine.11. The modified phosphoramidite according to wherein said modified base is deuteratedguanine12. The modified phosphoramidite according to wherein said modified base is deuteratedcytosine.13. The modified phosphoramidite according to wherein said modified base is deuterateduracil.14. The modified oligonucleotide according to wherein the ribose sugar is partially deuterated.16. The deuterated oligonucleotide solid support according to wherein said R1 is dimethoxytrityl protecting group claim 15 , R2 is t-butyldimethylsilyl protecting group claim 15 , R4 is succinyl Icaa claim 15 , and R4 is CPG.17. The deuterated oligonucleotide solid support according to wherein said nucleobase is a ...

Подробнее
Номер записи: 86
06-02-2014 дата публикации

PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION

Номер: US20140039179A1
Автор: DE CLERCQ Erik, HERDEWIJN Piet, PANNECOUQUE Christophe, WU Tongfei
Принадлежит:

The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. These compounds can be described by general formula (II) 2. The process of claim 1 , wherein Ris an O-benzoyl group.3. The process of claim 1 , wherein the Lewis acid catalyst is SnCl.4. The process of claim 1 , further comprising a step of N-protecting the nucleobase with an acyl group prior to the coupling step.5. The process of claim 4 , wherein the acyl group is a benzoyl group or an acetyl group.6. The process of claim 1 , wherein the coupling step is carried out from 0° C. to room temperature.7. The process of claim 1 , further comprising a step of silylating the nucleobase prior to the coupling step.8. The process of claim 7 , wherein silylating is performed with hexamethyldisilane.9. The process of claim 8 , wherein silylating is performed in the presence of ammonium sulphate.10. The process of claim 1 , wherein Ris ORand Ris hydrogen claim 1 , further comprising a step of selectively protecting Rprior to the coupling step.11. The process of claim 1 , wherein Rand Rare each isopropyl.12. The process of claim 1 , wherein Ris benzyl.13. The process of claim 1 , wherein n is 1.14. The process of claim 11 , wherein Ris benzyl.15. The process of claim 11 , wherein n is 1.16. The process of claim 12 , wherein n is 1.17. The process of claim 4 , further comprising a step of deprotecting the nucleobase after the coupling step claim 4 , said deprotecting step being performed under basic conditions.18. The process of claim 17 , wherein said deprotecting step is performed with saturated ammonia in methanol.19. The process of claim 1 , wherein Rand Rare each hydrogen claim 1 , further comprising a final hydrolysis step.20. The process of claim 19 , wherein said final hydrolysis step is performed by treatment with a ...

Подробнее
Номер записи: 87
13-02-2014 дата публикации

Processes for the preparation of regadenoson and a new crystalline form thereof

Номер: US20140045781A1
Автор: Chun Ma, Luzviminda T Wooldridge, Sourena Nadji
Принадлежит: Reliable Biopharmaceutical LLC

This disclosure relates to an improved process for the preparation of regadenoson, pharmaceutically acceptable salts thereof, and hydrates thereof, and for the preparation of intermediates useful in the synthesis of regadenoson. The disclosure also relates to a new crystalline form of regadenoson. Processes for the preparation of the crystalline form, compositions containing the crystalline form, and methods of use thereof are also described.

Подробнее
Номер записи: 88
13-02-2014 дата публикации

METHOD FOR ISOLATING NUCLEIC ACIDS AND COMPOSITION USED THEREFOR

Номер: US20140046050A1
Автор: Chen Yi-Chang, TSAI Jane S-C
Принадлежит: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

The disclosure provides a composition and method for isolating nucleic acids, in which the composition includes at least one halocarbon, at least one salt and at least one surfactant. Mixing the composition and a biosample to form a homogenized solution, nucleic acids in the solution can be easily isolated with a simple treatment and good yield. 1. A composition for isolating nucleic acids , comprising at least one halocarbon , at least one salt , and at least one surfactant ,wherein the composition contains 1˜70% by weight of the halocarbon based on the total weight of the composition.2. The composition as claimed in claim 1 , wherein the halocarbon comprises perfluorocarbons.3. The composition as claimed in claim 2 , wherein the perfluorocarbon comprises tetrafluoromethane claim 2 , hexafluoroethane claim 2 , perfluropropane claim 2 , perfluorobutane claim 2 , perfluoropentane claim 2 , perfluorohexane claim 2 , perfluoroheptane or perfluorooctane.4. The composition as claimed in claim 1 , wherein the salt comprises alkali salts claim 1 , alkali earth salts claim 1 , guanidine salts or a combination thereof.5. The composition as claimed in claim 1 , wherein the composition contains 5˜80% by weight of the salt based on the total weight of the composition.6. The composition as claimed in claim 1 , wherein the surfactant comprises polysorbate claim 1 , polyethylene glycol p-(1 claim 1 ,1 claim 1 ,3 claim 1 ,3-tetramethylbutyl)-phenyl ether or a combination thereof.7. The composition as claimed in claim 1 , wherein the composition contains 0.01˜10% by weight of the surfactant based on the total weight of the composition.8. The composition as claimed in claim 1 , wherein the composition further comprises magnetic particles.9. The composition as claimed in claim 8 , wherein the magnetic particle comprises ferrite nanoparticles claim 8 , ultra-small superparamagnetic iron oxide nanoparticles or a combination thereof.10. The composition as claimed in claim 1 , wherein the ...

Подробнее
Номер записи: 89
20-02-2014 дата публикации

2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES

Номер: US20140051846A1
Автор: Beaucage Serge L., Cieslak Jacek
Принадлежит: TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service

Disclosed are O-protected compounds of the formula (I): wherein B is an optionally protected nucleobase, and R-Rare as described herein, a method of preparing such compounds, and a method of preparing oligonucleotides such as RNA starting from such compounds. The O-protected compounds have one or more advantages, for example, the 2′-O-protected compound is stable during the various reaction steps involved in oligonucleotide synthesis; the protecting group can be easily removed after the synthesis of the oligonucleotide, for example, by reaction with tetrabutylammonium fluoride; and/or the O-protected groups do not generate DNA/RNA alkylating side products, which have been reported during removal of 2′-O-(2-cyanoethyl)oxymethyl or 2′-O-[2-(4-tolylsulfonyl)ethoxymethyl groups under similar conditions. 2. The compound of claim 1 , wherein the optionally protected nucleobase or the nucleobase is selected from the group consisting of cytosine claim 1 , adenine claim 1 , guanine claim 1 , uracil claim 1 , thymine claim 1 , xanthine claim 1 , hypoxanthine claim 1 , alkyl derivatives thereof claim 1 , amino derivatives thereof claim 1 , halo derivatives thereof claim 1 , 2- or 8-amino adenine claim 1 , 2- or 8-alkyl adenine claim 1 , 5-halo uracil claim 1 , 5-halo cytosine claim 1 , 2 claim 1 ,6-diaminopurine claim 1 , 6-aza uracil claim 1 , 4-thio uracil claim 1 , 5-trifluoromethyl uracil claim 1 , 5-trifluoromethyl cytosine claim 1 , 6-aza thymine claim 1 , 6-thioguanine claim 1 , 7-deazaadenine claim 1 , 7-deazaguanine claim 1 , 8-mercapto adenine claim 1 , 8-thioalkyl adenine claim 1 , 8-hydroxyl/oxo adenine claim 1 , 8-mercapto guanine claim 1 , 8-thioalkyl guanine claim 1 , and 8-hydroxyl/oxo guanine claim 1 , 1-methyladenine claim 1 , 2-methyladenine claim 1 , N-methyladenine claim 1 , N-isopentyladenine claim 1 , 2-methylthio-N-isopentyladenine claim 1 , N claim 1 ,N-dimethyladenine claim 1 , 8-bromoadenine claim 1 , 2-thiocytosine claim 1 , 3-methylcytosine claim 1 ...

Подробнее
Номер записи: 90
20-02-2014 дата публикации

METHOD FOR ISOLATING DNA

Номер: US20140051847A1
Автор: Abdullah Norhani, Hassan Mohd Ali, Rahim Abdul Raha, Sakai Kenji, Shamsara Mehdi, Shirai Yoshihito, Tabatabaei Meisam, Wright Ander-Denis G., Zakaria Mohd Rafein
Принадлежит: UNIVERSITI PUTRA MALAYSIA

The present invention provides a method for the isolation of nucleic acid from microbial cells in an environmental sample. The method includes preparing a suspension of the environmental sample, lysing the suspended sample with a buffered solution, adding sodium dodecylsulfate solution to the lysed suspended sample, carrying out solvent extraction and separation to obtain an aqueous phase, reacting the aqueous phase with solvents to generate an insoluble precipitate containing nucleic acid, and isolating the nucleic acid therefrom, thereby releasing high molecular weight nucleic acid pellets from the cells. 1. A method for isolating nucleic acid from microbial cells in an environmental sample , including:(i) preparing a suspension of the environmental sample;(ii) lysing the suspended sample with a buffered solution;(iii) adding sodium dodecylsulfate solution to the lysed suspended sample;(iv) subjecting the product of step (iii) to solvent extraction and separation to obtain an aqueous phase;(v) reacting the aqueous phase with solvents to generate an insoluble precipitate containing nucleic acid; and(vi) isolating the nucleic acid therefrom, thereby releasing high molecular weight nucleic acid pellets from the cells.2. A method according to claim 1 , further comprising subjecting nucleic acid pellets of step (vi) to further nucleic acid purification.3. A method according to claim 2 , wherein further nucleic acid purification includes re-suspending the nucleic acid in a solvent and buffered solution claim 2 , and isolating the nucleic acid therefrom.4. A method according to claim 3 , wherein the solvent is ethanol and the buffered solution is TE buffer.5. A method according to claim 1 , wherein the isolated nucleic acid is stored at 4° C.6. A method according to claim 1 , wherein the environmental sample is selected from the group consisting of water or liquid claim 1 , soil claim 1 , aerosol claim 1 , stool claim 1 , sludge claim 1 , sewage samples and plant ...

Подробнее
Номер записи: 91
20-02-2014 дата публикации

LACTOSE CRYSTALLISATION

Номер: US20140051850A1
Автор: Stephenson Paul, Styles Anthony James
Принадлежит:

The invention relates to a method of crystallising lactose from a lactose-containing liquid comprising the steps of providing a lactose-containing liquid comprising less than 80% by weight total solids, providing an evaporator system that comprises a heat exchanger and an evaporation vessel, the heat exchanger comprising a tube or tubes that define a flowpath having an inlet and an outlet, heating the lactose-containing liquid in the heat exchanger to about 50 to about 90° C. such that the lactose-containing liquid passes along the flowpath by forced circulation or thermo-siphoning, concentrating the lactose-containing liquid in the evaporation vessel, to generate crystallised lactose in the lactose-containing liquid in the evaporator system. 1. A method of crystallising lactose from a lactose-containing liquid comprising providing a lactose-containing liquid comprising less than 80% by weight total solids ,providing an evaporator system that comprises a rising film or flooded tube heat exchanger and an evaporation vessel,heating the lactose-containing liquid in the rising film or flooded tube heat exchanger to about 50 to about 90° C.,concentrating the lactose-containing liquid in the evaporation vessel,to generate crystallised lactose in the lactose-containing liquid in the evaporator system.2. A method of crystallising lactose from a lactose-containing liquid comprisingproviding a lactose-containing liquid comprising less than 80% by weight total solids,providing an evaporator system that comprises a heat exchanger and an evaporation vessel, the heat exchanger comprising a tube or tubes that define a flowpath having an inlet and an outlet,heating the lactose-containing liquid in the heat exchanger to about 50 to about 90° C. such that the lactose-containing liquid passes along the flowpath by forced circulation or thermo-siphoning,concentrating the lactose-containing liquid in the evaporation vessel,to generate crystallised lactose in the lactose-containing ...

Подробнее
Номер записи: 92
27-02-2014 дата публикации

Use of Hepcidin Binding Nucleic Acids for Depletion of Hepcidin From the Body

Номер: US20140057970A1
Автор: Klare Nicola, Klussmann Sven, Schwobel Frank, TURNER John
Принадлежит:

The present invention is related to a method for reducing the level of hepcidin in a body fluid from a subject, comprising 1104-. (canceled)105. A method for reducing the level of hepcidin in a body fluid from a subject , comprisinga) providing a nucleic acid that binds hepcidin,b) bringing the nucleic acid into contact with the body fluid under conditions that allow the nucleic acid to bind the hepcidin forming a complex of hepcidin and the nucleic acid, andc) removing the complex from the body fluid or removing the hepcidin from the body fluid.106. The method according to claim 105 , wherein the nucleic acid comprises in 5→3′ direction a first terminal stretch of nucleotides claim 105 , a central stretch of nucleotides and a second terminal stretch of nucleotides claim 105 , or a second terminal stretch of nucleotides claim 105 , a central stretch of nucleotides and a first terminal stretch of nucleotides claim 105 , wherein the central stretch of nucleotides comprises 32 to 40 nucleotides or 32 to 35 nucleotides.107. The method according to claim 106 , wherein the central stretch of nucleotides comprises 5′ RKAUGGGAKUAAGUAAAUGAGGRGUWGGAGGAAR 3′ (SEQ ID NO:182) or 5′ RKAUGGGAKAAGUAAAUGAGGRGUWGGAGGAAR 3′ (SEQ ID NO:183).108. The method according to claim 106 , wherein the central stretch of nucleotides comprises five to eight nucleotides claim 106 , and the second terminal stretch of nucleotides comprises five to eight nucleotides.1093′; wherein X. The method according to claim 106 , wherein the central stretch of nucleotides comprises 5′ XXXSBSBC3′ and the second terminal stretch of nucleotides comprises 5′ GVBVYXXXis A or absent claim 106 , Xis G or absent claim 106 , Xis B or absent claim 106 , Xis S or absent claim 106 , Xis C or absent claim 106 , and Xis U or absent.110. The method according to claim 105 , wherein the nucleic acid comprises SEQ ID NO: 115 claim 105 , SEQ ID NO: 116 claim 105 , SEQ ID NO: 117 claim 105 , SEQ ID NO: 118 claim 105 , SEQ ID NO: ...

Подробнее
Номер записи: 93
06-03-2014 дата публикации

MINICIRCLE VECTOR PRODUCTION

Номер: US20140065705A1
Автор: JECHLINGER Wolfgang, Lubitz Werner, MAYRHOFER Peter
Принадлежит:

A plasmid is provided comprising the following functional units: a prokaryotic origin of replication, a marker sequence, two specific recombinase recognition sequences and a multiple cloning site, whereby it comprises a gene coding for a sequence specific recombinase, whereby the units are arranged on the plasmid in such a way that the plasmid is divided into a miniplasmid and a minicircle upon expression of the sequence specific recombinase, said miniplasmid comprising the prokaryotic origin of replication, the marker sequence and the gene for the sequence specific recombinase and said minicircle comprising the multiple cloning site. 131-. (canceled)32. A method for isolating a miniplasmid or a minicircle , said miniplasmid or said minicircle comprising a recognition sequence which is a lac operator site by binding said miniplasmid or minicircle to a Lad repressor protein.33. Method according to claim 32 , wherein the recognition sequence consists of repeats of lac operator sequences.34. Method according to claim 32 , wherein the recognition sequence consists of repeats of lac operator sequences which are separated by a spacer.35. Method according to claim 34 , wherein the repeats of the lac operator sequences are two repeats separated by a spacer.36E. coli,E. coli.. Method according to claim 35 , wherein the spacer is an origin of replication for bacteriophages specific for optionally an origin of replication for filamentous or icosaedric bacteriophages specific for37. Method according to claim 32 , wherein the lac operator site has a high affinity to the LacI repressor protein (lacOs sequences).38. Method according to claim 32 , wherein the Lad repressor is mutated in such a way that the binding of the repressor protein to the lac operon can be regulated claim 32 , optionally the LacI repressor is only stable at a specific temperature.39. Method according to claim 32 , wherein the minicircle or miniplasmid is isolated by immobilisation to a solid support via the ...

Подробнее
Номер записи: 94
13-03-2014 дата публикации

METHODS OF DEPLETING A TARGET MOLECULE IN A SAMPLE AND KITS FOR PRACTICING THE SAME

Номер: US20140073528A1
Автор: Betts Craig, Bostick Magnolia, Espinosa Eric
Принадлежит:

Provided are methods of depleting a target molecule in a sample. The methods include contacting a target molecule with a free radical-generating system and generating free radicals from the free radical-generating system to deplete the target molecule in the sample. Kits for practicing the subject methods are also provided. 1. A method of depleting a target molecule in a sample , the method comprising:(a) contacting a target molecule with a free radical-generating system; and(b) generating free radicals from the free radical-generating system to deplete the target molecule in the sample.2. The method according to claim 1 , wherein the free radical-generating system comprises a catalyst and a catalyst-binding agent.3. The method according to claim 2 , wherein the catalyst-binding agent comprises a targeting molecule that specifically binds to the target molecule.4. The method according to claim 2 , wherein the catalyst-binding agent is a chelating agent.5. (canceled)6. The method according to claim 2 , wherein the catalyst is a metal.7. The method according to claim 6 , wherein the metal is selected from copper and iron.8. The method according to claim 7 , wherein the catalyst is iron and the catalyst-binding agent is EDTA.9. The method according to claim 1 , wherein the target molecule is a target nucleic acid.10. The method according to claim 9 , wherein the target nucleic acid is a ribonucleic acid (RNA).11. (canceled)12. The method according to claim 10 , wherein the RNA is an rRNA.13. The method according to claim 9 , wherein the target nucleic acid is a deoxyribonucleic acid (DNA).14. The method according to claim 9 , wherein the targeting molecule is selected from the group consisting of: a nucleic acid that specifically hybridizes to the target nucleic acid claim 9 , a polypeptide claim 9 , an intercalating agent claim 9 , and an aptamer.15. The method according to claim 14 , wherein the targeting molecule is a nucleic acid that specifically hybridizes to the ...

Подробнее
Номер записи: 95
20-03-2014 дата публикации

METHODS FOR REDUCING NUCLEIC ACID DAMAGE

Номер: US20140080721A1
Автор: Fritzilas Epameinondas, Gormley Niall Anthony, Hall Kevin, Ioannou Avgousta, Klausing Kay, MOORE John, Rigatti Roberto, Shen Min-Jui Richard, Smith Vincent Peter
Принадлежит: Illumina, Inc.

Provided herein is a method of inhibiting degradation of nucleic acids during a nucleic acid processing step selected from fragmentation and detection comprising contacting the nucleic acids with a solution comprising gallic acid, analogues, derivatives thereof or mixtures thereof, during the processing step, wherein the contacting inhibits degradation of the nucleic acids. Also provided herein is a method of inhibiting light-induced degradation of nucleic acids. Additionally, provided herein is a method of reducing or inhibiting nucleic acid damage during preparation of a nucleic acid sample comprising fragmenting the nucleic acid sequences in the sample in a solution comprising one of more compounds, the compounds inhibiting degradation of the nucleic acid sequences in the sample. 1. A method of inhibiting degradation of nucleic acids during a nucleic acid processing step selected from fragmentation and detection comprising contacting the nucleic acids with a solution comprising gallic acid , analogues , derivatives , or mixtures thereof during the processing step , wherein the contacting inhibits degradation of the nucleic acids.2. The method of claim 1 , wherein the nucleic acids are in an array of nucleic acids attached to a support.3. The method of claim 1 , wherein the gallic acid claim 1 , analogues claim 1 , derivatives claim 1 , or mixtures thereof is present in a concentration ranging from between about 10 mM to about 200 mM.46-. (canceled)7. The method of claim 1 , wherein the processing step is a detection processing step.8. The method of claim 7 , wherein the detection processing step comprises irradiating the nucleic acids.9. The method of claim 8 , wherein the irradiating is conducted in a range from about 360 nm to about 800 nm.10. The method of claim 8 , wherein the irradiating is conducted with a light source having power in a range between about 5 to about 500 milliwatts.11. The method of claim 8 , wherein the irradiating is conducted for a time ...

Подробнее
Номер записи: 96
03-04-2014 дата публикации

PROTEIN REMOVAL AGENT

Номер: US20140093937A1
Автор: Merkiene Egle, Tiknius Vitalis
Принадлежит:

The present invention provides compositions, methods and kits for the removal of proteins from complex reaction mixtures useful in majority workflows of molecular biology research experiments. More specifically, such compositions, methods and kits are useful in such processes as purification of nucleic acids from biological samples or after their treatment with specific enzymes, when residual enzyme activity in reaction mixture is not compatible with downstream applications. 1. A composition for removing protein contaminants from a-solution containing a target nucleic acid , the composition comprising(i) a polyacid comprising a polycarboxylic acid, a polyphosphonic acid, or a polycarboxylate or polyphosphonate salt; and(ii) a solid phase comprising a functionalized silica surface.2. The composition of where the solid phase comprises silica.3. The composition of where the solid phase comprises particles.4. The composition of where the particles are substantially spherical and have a diameter in the range of from 3 μm to 15 μm.5. The composition of where the particles have pores with a diameter of from 10 nm to 100 nm.6. The composition of where the functionalized silica bears anionic or neutral substituent groups that are (i) polar claim 1 , other than phenol claim 1 , and/or (ii) comprise a Cto Calkyl chain.7. The composition of where the substituent groups are selected from{'sub': 2', 'n, 'cyanoalkyl groups (CN—(CH)—) where n is an integer of at least 3;'}{'sub': 3', '2', 'm, 'short chain alkyl groups (CH—(CH)—) where m is 0, 1, or 2;'}{'sub': 3', '2', 'l, 'sulfoalkyl groups (HSO—(CH)—) where l is an integer in the range 2 to 6;'}{'sub': 3', '3', 'p, 'alkanoyl groups (CH—(CH)—CO—O—) where p is 0, 1, or 2;'}{'sub': 2', '2', 'r', '2', 'r', '2', '2', 't, 'a diol ((OH)—CH—(CH)—) or hydroxyl OH—(CH)— where r is zero or an integer in the range 1 to 5, or mixed diol CHOH—CHOH—(CH)—;'}{'sub': 6', '9', '2', '2', 't, 'a cyclohexyldiol CH(OH)—(CH)—;'}{'sub': 2', 't', '2', '6 ...

Подробнее
Номер записи: 97
03-04-2014 дата публикации

POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA

Номер: US20140093944A1
Автор: EWERT MATT
Принадлежит: UNIVERSITY OF SOUTH FLORIDA

The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. 1. A method of permitting nucleic acid isolation from a biological sample containing a pathogen containing the nucleic acid , the method comprising:contacting the sample with aurintricarboxylic acid (ATA), a DNase, and an enzyme that will break down a nuclear membrane; andisolating the nucleic acid by extracting the nucleic acid.2. The method of claim 1 , wherein the method further comprises contacting the sample with streptokinase and plasminogen.3. The method of claim 1 , wherein the concentration of ATA is between 10 and 200 mM.4. The method of claim 1 , wherein the DNase is an endonuclease.5. The method of claim 1 , wherein the enzyme that will break down a nuclear membrane is Phospholipase A.6. The method of claim 1 , wherein the method further comprises contacting the sample with methyl 6-O—(N-heptylcarbamoyl)-alpha-D-glucopyranoside.7. The method of claim 6 , wherein the method further comprises contacting the sample with a saponin.8. The method of claim 1 , wherein the biological sample is blood.9. The method of claim 1 , wherein the pH of the sample is brought to about 7.8.10. The method of claim 1 , wherein the aurintricarboxylic acid (ATA) claim 1 , the DNase claim 1 , and the enzyme that will break down a nuclear membrane are in the same composition.11. The method of claim 1 , wherein the method further comprises contacting the sample with urea and diethylenetriaminepentaacetate (DTPA).12. The method of claim 1 , wherein the method further comprises contacting the sample with proteinase K.13. The method of claim 11 , wherein contacting the sample ...

Подробнее
Номер записи: 98
03-04-2014 дата публикации

Method for the purification of decitabine

Номер: US20140094598A1
Автор: Daniel James Coughlin
Принадлежит: JOHNSON MATTHEY PLC

A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension. The forming step may further comprise after adding ethanol to provide a mixture of dimethylacetamide and ethanol: cooling the mixture; isolating the solid decitabine present in the cooled mixture; and evaporating residual dimethylacetamide and ethanol from the solid decitabine to provide the purified decitabine. The mixture of dimethylacetamide and ethanol may be heated. The purification method preferably results in decitabine having a ratio of the β-anomer of decitabine to the α-anomer of decitabine of at least about 99.9:0.1.

Подробнее
Номер записи: 99
10-04-2014 дата публикации

VESICLE CAPTURING DEVICES AND METHODS FOR USING SAME

Номер: US20140099649A1
Автор: Mitsuhashi Masato
Принадлежит:

Provided is a device that collects vesicles and vesicle-like materials from biological fluids. Such devices comprise at least one sample loading region; at least one corresponding vesicle-capture material, wherein said vesicle-capture material comprises glass-like materials; and at least one corresponding sample receiving region, wherein passage of the biological fluid from the sample loading region through the vesicle capture material and into the sample receiving region results in the capture of vesicles. Additional methods provide for a method of isolating vesicles and vesicle-like materials from biological fluids are also provided. 1. A method of isolating vesicles from biological fluid , comprising:(a) obtaining a biological fluid sample comprising said vesicles;(b) loading at least a portion of said biological fluid sample into a sample loading region of a vesicle capture device;(c) passing said biological fluid sample from said sample loading region through a vesicle-capture material in said vesicle capture device, said vesicle-capture material comprising at least a first layer and a second layer of glassfiber, thereby producing a supernatant; and(d) passing said supernatant to a sample receiving region of said vesicle capture device and discarding the supernatant,wherein said passings result in capture of said vesicles from said biological fluid sample on or in said vesicle-capture material.2. The method of wherein said vesicle-capture material captures vesicles sized from about 0.6 microns to about 1.6 microns in diameter.3. The method of claim 1 , wherein said vesicle-capture material captures exosomes or other vesicles ranging in size from about 0.020 to about 1.0 microns.4. (canceled)5. (canceled)6. The method of claim 1 , wherein step (c) comprises passing said biological fluid through said first layer of glassfiber so as to capture material from said biological sample that is about 1.6 microns or greater in diameter.7. The method of claim 6 , wherein ...

Подробнее
Номер записи: 100